<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">20142</article-id><article-id pub-id-type="doi">10.7554/eLife.20142</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>APP modulates KCC2 expression and function in hippocampal GABAergic inhibition</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-63653"><name><surname>Chen</surname><given-names>Ming</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-64416"><name><surname>Wang</surname><given-names>Jinzhao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-75741"><name><surname>Jiang</surname><given-names>Jinxiang</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-75742"><name><surname>Zheng</surname><given-names>Xingzhi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-64417"><name><surname>Justice</surname><given-names>Nicholas J</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-64418"><name><surname>Wang</surname><given-names>Kun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-77817"><name><surname>Ran</surname><given-names>Xiangqian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-64419"><name><surname>Li</surname><given-names>Yi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-64420"><name><surname>Huo</surname><given-names>Qingwei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-64421"><name><surname>Zhang</surname><given-names>Jiajia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-64422"><name><surname>Li</surname><given-names>Hongmei</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-64423"><name><surname>Lu</surname><given-names>Nannan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-64424"><name><surname>Wang</surname><given-names>Ying</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-13397"><name><surname>Zheng</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-64425"><name><surname>Long</surname><given-names>Cheng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-52023"><name><surname>Yang</surname><given-names>Li</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7448-8588</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">School of Life Sciences</institution>, <institution>South China Normal University</institution>, <addr-line><named-content content-type="city">Guangzhou</named-content></addr-line>, <country>China</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">School of Psychology and Center for Studies of Psychological Application</institution>, <institution>South China Normal University</institution>, <addr-line><named-content content-type="city">Guangzhou</named-content></addr-line>, <country>China</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Brain Science Institute</institution>, <institution>South China Normal University</institution>, <addr-line><named-content content-type="city">Guangzhou</named-content></addr-line>, <country>China</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Institute of Molecular Medicine</institution>, <institution>University of Texas Health Sciences Center</institution>, <addr-line><named-content content-type="city">Houston</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Huffington Center on Aging</institution>, <institution>Baylor College of Medicine</institution>, <addr-line><named-content content-type="city">Houston</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Guangdong Key Laboratory of Mental Health and Cognitive Science</institution>, <institution>South China Normal University</institution>, <addr-line><named-content content-type="city">Guangzhou</named-content></addr-line>, <country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kim</surname><given-names>Eunjoon</given-names></name><role>Reviewing editor</role><aff id="aff7"><institution>Institute for Basic Science, Korea Advanced Institute of Science and Technology</institution>, <country>Republic of Korea</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>yang_li@m.scnu.edu.cn</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>05</day><month>01</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>6</volume><elocation-id>e20142</elocation-id><history><date date-type="received"><day>28</day><month>07</month><year>2016</year></date><date date-type="accepted"><day>16</day><month>12</month><year>2016</year></date></history><permissions><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-20142-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.20142.001</object-id><p>Amyloid precursor protein (APP) is enriched at the synapse, but its synaptic function is still poorly understood. We previously showed that GABAergic short-term plasticity is impaired in <italic>App</italic> knock-out (<italic>App<sup>-/-</sup></italic>) animals, but the precise mechanism by which APP regulates GABAergic synaptic transmission has remained elusive. Using electrophysiological, biochemical, moleculobiological, and pharmacological analysis, here we show that APP can physically interact with KCC2, a neuron-specific K<sup>+</sup>-Cl<sup>-</sup> cotransporter that is essential for Cl<sup>-</sup> homeostasis and fast GABAergic inhibition. APP deficiency results in significant reductions in both total and membrane KCC2 levels, leading to a depolarizing shift in the GABA reversal potential (E<sub>GABA</sub>). Simultaneous measurement of presynaptic action potentials and inhibitory postsynaptic currents (IPSCs) in hippocampal neurons reveals impaired unitary IPSC amplitudes attributable to a reduction in Î±1 subunit levels of GABA<sub>A</sub>R. Importantly, restoration of normal KCC2 expression and function in <italic>App<sup>-/-</sup></italic> mice rescues E<sub>GABA</sub>, GABA<sub>A</sub>R Î±1 levels and GABA<sub>A</sub>R mediated phasic inhibition. We show that APP functions to limit tyrosine-phosphorylation and ubiquitination and thus subsequent degradation of KCC2, providing a mechanism by which APP influences KCC2 abundance. Together, these experiments elucidate a novel molecular pathway in which APP regulates, via protein-protein interaction with KCC2, GABA<sub>A</sub>R mediated inhibition in the hippocampus.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.001">http://dx.doi.org/10.7554/eLife.20142.001</ext-link></p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.20142.002</object-id><title>eLife digest</title><p>Alzheimerâs disease is the most common form of dementia. One of the hallmarks of the disease is the formation of sticky protein clumps called amyloid plaques in the brain. These plaques are formed from specific fragments of a protein called APP. The intact form of APP is essential for synapses (the junctions across which neurons transmit signals) to form and work correctly.</p><p>The hippocampus is one of the first brain regions to be affected in Alzheimerâs disease and is important for forming memories and emotions. In the hippocampus, GABA<sub>A</sub> receptors at synapses normally tightly regulate synaptic signaling by reducing the ability of the receiving neuron to respond, but this inhibition is disrupted in Alzheimerâs disease. Studies suggest that APP can affect how GABA<sub>A</sub> receptors transmit signals, but it is not known how it does so. One possibility is that APP regulates a protein called KCC2 that helps to maintain the inhibitory effect of GABA<sub>A</sub> receptors.</p><p>To investigate this, Chen et al. genetically modified mice to lack the gene that produces APP. These mice had a lower level of KCC2 in their hippocampus than normal mice, and their GABA<sub>A</sub> receptors were less able to inhibit synaptic signaling. Further experiments demonstrated that APP physically interacts with KCC2 and maintains normal levels of the protein by preventing it from being chemically modified and degraded.</p><p>Chen et al. also showed that treating mice that lack APP with specific compounds can restore KCC2 activity and return the behavior of synaptic GABA<sub>A</sub> receptors to normal. Future studies in mice (and eventually people) that exhibit symptoms of Alzheimer's disease will help to determine whether KCC2 is important in the development of the disease. If so, modifying the levels of the KCC2 protein in the brain could potentially help to slow down memory loss in Alzheimerâs disease.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.002">http://dx.doi.org/10.7554/eLife.20142.002</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>APP</kwd><kwd>KCC2</kwd><kwd>hippocampus</kwd><kwd>GABA reversal potential</kwd><kwd>IPSC</kwd><kwd>protein-protein interaction</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31171018</award-id><principal-award-recipient><name><surname>Long</surname><given-names>Cheng</given-names></name><name><surname>Yang</surname><given-names>Li</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003453</institution-id><institution>Natural Science Foundation of Guangdong Province</institution></institution-wrap></funding-source><award-id>2014A030313418</award-id><principal-award-recipient><name><surname>Long</surname><given-names>Cheng</given-names></name><name><surname>Yang</surname><given-names>Li</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31171355</award-id><principal-award-recipient><name><surname>Long</surname><given-names>Cheng</given-names></name><name><surname>Yang</surname><given-names>Li</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003453</institution-id><institution>Natural Science Foundation of Guangdong Province</institution></institution-wrap></funding-source><award-id>2014A030313440</award-id><principal-award-recipient><name><surname>Long</surname><given-names>Cheng</given-names></name><name><surname>Yang</surname><given-names>Li</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>The Science and Technology Division of Guangdong Province</institution></institution-wrap></funding-source><award-id>2013KJCX0054</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Li</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>The Science and Technology Division of Guangdong Province</institution></institution-wrap></funding-source><award-id>201607010320</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Li</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>APP interacts with KCC2 to limit the latter from tyrosine-phosphorylation and ubiquitination and thus subsequent degradation, revealing a novel molecular pathway in which APP regulates GABAergic signaling and thus inhibition in the hippocampus.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>APP is a type I single pass transmembrane protein highly expressed in the central nervous system (CNS) which is processed by Î±-, Î²-, and Î³-secretases (<xref ref-type="bibr" rid="bib21">Hardy and Selkoe, 2002</xref>) to generate beta amyloid (AÎ²) peptide fragments that comprise the amyloid plaques found in Alzheimerâs disease (AD) patients post-mortem. The deleterious impact of AÎ² has been studied extensively, with the recent discovery of the potent toxicity of AÎ² oligomers on neuronal and synaptic activities (<xref ref-type="bibr" rid="bib22">Hsieh et al., 2006</xref>; <xref ref-type="bibr" rid="bib26">Kim et al., 2006</xref>; <xref ref-type="bibr" rid="bib52">Wei et al., 2010</xref>). Despite advances in our understanding of how AÎ² generation drives AD progression, the physiologic role of APP has proven more difficult to elucidate (<xref ref-type="bibr" rid="bib13">De Strooper and Annaert, 2000</xref>). APP has been detected in vesicular fractions of dendrites and axons (<xref ref-type="bibr" rid="bib38">Schubert et al., 1991</xref>), suggesting a role for APP in synaptic activity. Moreover, we have shown that APP is required for normal adult neurogenesis (<xref ref-type="bibr" rid="bib50">Wang et al., 2014a</xref>) and formation of the neuromuscular junction (<xref ref-type="bibr" rid="bib49">Wang et al., 2009</xref>; <xref ref-type="bibr" rid="bib54">Yang et al., 2007</xref>).</p><p>Many lines of evidence have suggested that APP function can impact the electrophysiological properties of neurons (<xref ref-type="bibr" rid="bib25">Kamenetz et al., 2003</xref>; <xref ref-type="bibr" rid="bib27">Klevanski et al., 2015</xref>; <xref ref-type="bibr" rid="bib32">Palop and Mucke, 2010</xref>; <xref ref-type="bibr" rid="bib34">Priller et al., 2006</xref>; <xref ref-type="bibr" rid="bib40">Selkoe, 2002</xref>; <xref ref-type="bibr" rid="bib50">Wang et al., 2014a</xref>; <xref ref-type="bibr" rid="bib55">Yang et al., 2009</xref>). Paired-pulse inhibition of GABAergic IPSCs is significantly reduced in <italic>App<sup>-/-</sup></italic> hippocampal slices (<xref ref-type="bibr" rid="bib39">Seabrook et al., 1999</xref>). However, the molecular mechanism underlying this phenotype is not fully understood. Given that GABAergic function is commonly disturbed in many neuronal disorders including AD (<xref ref-type="bibr" rid="bib6">Braat and Kooy, 2015a</xref>; <xref ref-type="bibr" rid="bib46">Verret et al., 2012</xref>), identifying mechanisms whereby APP regulates GABAergic signaling and synaptic inhibition may provide a link between the endogenous function of APP and the etiology of AD.</p><p>The K<sup>+</sup>-Cl<sup>-</sup> cotransporter, KCC2, is broadly expressed in neuronal membrane of the adult CNS (<xref ref-type="bibr" rid="bib24">Kaila et al., 2014</xref>). KCC2 functions in setting the proper intracellular Cl<sup>-</sup> concentration ([Cl<sup>-</sup>]<sub>i</sub>) by transporting Cl<sup>-</sup> against the concentration gradient (<xref ref-type="bibr" rid="bib1">Ben-Ari, 2002</xref>; <xref ref-type="bibr" rid="bib2">Ben-Ari et al., 2012</xref>). KCC2 maintains low [Cl<sup>-</sup>]<sub>i</sub> in mature neurons, which is essential for maintaining proper postsynaptic inhibition mediated by GABA<sub>A</sub> receptors (GABA<sub>A</sub>Rs) and glycine receptors (GlyRs) (<xref ref-type="bibr" rid="bib6">Braat and Kooy, 2015a</xref>; <xref ref-type="bibr" rid="bib24">Kaila et al., 2014</xref>; <xref ref-type="bibr" rid="bib35">Rivera et al., 1999</xref>). Impaired KCC2 activity and subsequent increases in [Cl<sup>-</sup>]<sub>i</sub> occur in several neurological disorders (<xref ref-type="bibr" rid="bib5">Boulenguez et al., 2010</xref>; <xref ref-type="bibr" rid="bib11">Coull et al., 2003</xref>; <xref ref-type="bibr" rid="bib44">Tang et al., 2016</xref>), leading to a depolarizing action of GABA<sub>A</sub>R mediated currents due to a positive shift of E<sub>GABA</sub>, and over-excitation of neuronal network activity (<xref ref-type="bibr" rid="bib1">Ben-Ari, 2002</xref>; <xref ref-type="bibr" rid="bib2">Ben-Ari et al., 2012</xref>; <xref ref-type="bibr" rid="bib4">Blaesse et al., 2009</xref>). Recent experiments on KCC2 processing suggest that the intrinsic ion transport rate, cell surface stability, and trafficking of plasmalemmal KCC2 are rapidly and reversibly modulated by the (de)phosphorylation of critical serine and tyrosine residues at the C-terminus of this protein (<xref ref-type="bibr" rid="bib29">Lee et al., 2010</xref>, <xref ref-type="bibr" rid="bib28">2007</xref>). Increased tyrosine phosphorylation of KCC2 leads to enhanced degradation of KCC2 and thus reduced KCC2 protein levels (<xref ref-type="bibr" rid="bib30">Lee et al., 2011</xref>, <xref ref-type="bibr" rid="bib29">2010</xref>). Therefore, abundance of KCC2 protein and the E<sub>GABA</sub> of a neuron can be regulated by phosphorylation and degradation of KCC2. However, which signaling pathways regulate these phosphorylation events and KCC2 degradation are largely unknown.</p><p>In the current study, we aimed to elucidate the synaptic mechanisms underlying APP regulation of hippocampal GABAergic inhibition. We show that APP mediates GABAergic inhibition via a direct protein-protein interaction with KCC2, which stabilizes KCC2 on the cell membrane. APP deficiency causes a loss of acting force holding KCC2 on site, resulting in increased KCC2 degradation via both tyrosine-phosphorylation and ubiquitination, decreased KCC2 levels and, sequentially, a depolarizing shift of E<sub>GABA</sub> and impairment in GABA<sub>A</sub>R activities.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>APP deficiency results in a depolarizing shift of E<sub>GABA</sub></title><p>In order to test the idea that loss of APP changes the cellular ionic balance of Cl<sup>-</sup>, thereby altering GABAergic transmission, we used gramicidin perforated patch clamp measurements in acute hippocampal brain slices (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) that allows maintenance of an intact intracellular chloride concentration to estimate the IV-relationship of GABAergic currents (<xref ref-type="bibr" rid="bib9">Chavas and Marty, 2003</xref>). We observed a positive shift of E<bold><sub>GABA</sub></bold> in <italic>App<sup>-/-</sup></italic> hippocampal CA1 compared to WT controls (WT, â83Â Â±Â 6 mV; <italic>App<sup>-/-</sup></italic>, â64Â Â±Â 5 mV; p=0.02) (<xref ref-type="fig" rid="fig1">Figure 1BâD</xref>), accompanying with identical resting membrane potentials (WT, â61Â Â±Â 1.4 mV; <italic>App<sup>-/-</sup></italic>, â59Â Â±Â 1.5 mV; p=0.2). We repeated perforated patch recordings in hippocampal cultures and observed a similar depolarizing shift of E<sub>GABA</sub> in <italic>App<sup>-/-</sup></italic> neuronal cultures (WT, â82.5Â Â±Â 4 mV; <italic>App<sup>-/-</sup></italic>, â67Â Â±Â 3.8 mV; p=0.02) (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>).<fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.20142.003</object-id><label>Figure 1.</label><caption><title>GABA reversal potential shifts toward depolarization in hippocampus of <italic>App<sup>-/-</sup></italic> mice.</title><p>(<bold>A</bold>) Slice preparations were made from the hippocampus and neurons were recorded in CA1 (inset). Pipettes were positioned to clamp neurons (Rec) while puffing molecules onto the cell (Puff). Scale bar: 10 Âµm. (<bold>B</bold>) Sample traces showing perforated patch recording of E<sub>GABA</sub> in WT and <italic>App<sup>-/-</sup></italic> hippocampal slices. Currents were recorded at the indicated holding potentials shown to the left of each trace. (<bold>C</bold>) Graph shows <italic>IâV</italic> plots for the traces shown in <bold>B</bold>. (<bold>D</bold>) Quantification of E<sub>GABA</sub> shows a significant depolarizing shift in <italic>App<sup>-/-</sup></italic> mice compared to WT controls (WT, nÂ =Â 16 cells from five mice; <italic>App<sup>-/-</sup></italic>, nÂ =Â 20 cells from five mice). *p&lt;0.05; Studentâs <italic>t</italic>-test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.003">http://dx.doi.org/10.7554/eLife.20142.003</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20142-fig1-v2"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20142.004</object-id><label>Figure 1âfigure supplement 1.</label><caption><title>GABA reversal potential shifts toward depolarization in <italic>App<sup>-/-</sup></italic> hippocampal cultures.</title><p>(<bold>A</bold>) Sample traces showing perforated patch recordings of E<sub>GABA</sub> in WT and <italic>App<sup>-/-</sup></italic> mice hippocampal cultures. Currents were recorded at the indicated holding potentials shown to the left of each trace. (<bold>B</bold>) Graph shows <italic>IâV</italic> plots for the traces shown in <bold>A</bold>. (<bold>C</bold>) Quantification of E<sub>GABA</sub> shows a significant depolarizing shift in <italic>App<sup>-/-</sup></italic> mice compared to WT (WT, nÂ =Â 14 cells from three independent cultures, 2â3 mice/per culture; <italic>App<sup>-/-</sup></italic>, nÂ =Â 12 cells from three independent cultures, 2â3 mice/per culture). *p&lt;0.05; Studentâs <italic>t</italic>-test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.004">http://dx.doi.org/10.7554/eLife.20142.004</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20142-fig1-figsupp1-v2"/></fig></fig-group></p></sec><sec id="s2-2"><title>uIPSC amplitude and GABA<sub>A</sub>R Î±1 subunit levels are reduced in <italic>App<sup>-/-</sup></italic> hippocampus</title><p>Loss of APP impairs GABAergic synaptic transmission (<xref ref-type="bibr" rid="bib39">Seabrook et al., 1999</xref>; <xref ref-type="bibr" rid="bib55">Yang et al., 2009</xref>). Given that we see a change in E<sub>GABA</sub> in hippocampal neurons, we next asked whether loss of APP alters hippocampal IPSCs and GABA<sub>A</sub>R expression. To do so, we performed dual whole-cell recordings in primary hippocampal cultures. We simultaneously evaluated electrically evoked presynaptic action potentials of a GABAergic interneuron labeled with GAD67<sup>+/GFP</sup>, while patching a neighboring glutamatergic neuron and recording post-synaptic unitary IPSCs (uIPSCs) at a holding potential of â60 mV (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The mean uIPSC amplitude, evoked by a single presynaptic action potential in the GABAergic neuron, was significantly reduced in <italic>App<sup>-/-</sup></italic> hippocampal cultures compared to WT control cultures (WT, 178Â Â±Â 42 pA; <italic>App<sup>-/-</sup></italic>, 80Â Â±Â 19 pA; p=0.03) (<xref ref-type="fig" rid="fig2">Figure 2BâC</xref>). Similarly, puffing the GABA<sub>A</sub>R agonist isoguvacine significantly reduced the amplitude of inhibitory currents in <italic>App<sup>-/-</sup></italic> neurons compared to WT neurons (WT, 245Â Â±Â 26 pA; <italic>App<sup>-/-</sup></italic>, 146Â Â±Â 24 pA; p=0.01) (<xref ref-type="fig" rid="fig2">Figure 2FâG</xref>). In contrast, the paired-pulse ratio (PPR) of uIPSCs in response to two consecutive action potentials in GABAergic neurons, at an inter-spike interval of 100 ms and 150 ms to assess synaptic release probability (<xref ref-type="bibr" rid="bib58">Zucker and Regehr, 2002</xref>), was similar between WT and <italic>App<sup>-/-</sup></italic> (<xref ref-type="fig" rid="fig2">Figure 2DâE</xref>) (100 ms; WT, 0.47Â Â±Â 0.04; <italic>App<sup>-/-</sup></italic>, 0.56Â Â±Â 0.03; p=0.2; 150 ms; WT, 0.51Â Â±Â 0.06; <italic>App<sup>-/-</sup></italic>, 0.55Â Â±Â 0.05; p=0.75). Consistent with impaired post-synaptic function accounting for these changes in APP mutants, we did not see a decrease in miniature IPSC (mIPSC) frequency, a measure of presynaptic efficacy (<xref ref-type="bibr" rid="bib15">Fiszman et al., 2005</xref>; <xref ref-type="bibr" rid="bib18">Goswami et al., 2012</xref>), when we compared <italic>App<sup>-/-</sup></italic> and WT hippocampal slices (Frequency; WT, 2.9Â Â±Â 0.8 Hz; <italic>App<sup>-/-</sup></italic> 2.6Â Â±Â 0.7 Hz; p=0.8) (<xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1CâD</xref>). Meanwhile mIPSC amplitude remained unchanged as well (Amplitude; WT, 14.8Â Â±Â 0.4 pA; <italic>App<sup>-/-</sup></italic>, 13.9Â Â±Â 0.8 pA; p=0.7) (<xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1CâD</xref>). In line with similar frequencies of mIPSCs in WT and <italic>App<sup>-/-</sup></italic> hippocampus, we observed identical numbers of GABAergic neurons in the hippocampus of <italic>App<sup>-/-</sup></italic> and WT mice (<xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1AâB</xref>,Â <xref ref-type="supplementary-material" rid="SD1-data">Figure 2âsource data 1</xref>). Finally, we looked at the abundance of GABA<sub>A</sub>Rs in the hippocampus of APP mutant and WT animals. <italic>App<sup>-/-</sup></italic> hippocampal lysates display reduced immunoreactivity of the Î±1 subunit, mediating fast inhibition, of the GABA<sub>A</sub>R but not the other GABA<sub>A</sub>R subunits, (<xref ref-type="fig" rid="fig2">Figure 2HâI</xref>, <xref ref-type="supplementary-material" rid="SD1-data">Figure 2âsource data 1</xref>). Together, these data suggest that loss of APP may cause postsynaptic deficits in GABA<sub>A</sub>R mediated GABAergic inhibition.<fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.20142.005</object-id><label>Figure 2.</label><caption><title>Decreased inhibitory IPSC amplitude and GABA<sub>A</sub>R Î±1 protein levels in <italic>App<sup>-/-</sup></italic> mice.</title><p>(<bold>A</bold>) Images of 12â14 DIV hippocampal cultures of <italic>Gad67<sup>+/GFP</sup></italic> mice. In the upper panel, under fluorescent illumination, GABAergic neurons appear green, and were stimulated (Sti) while recording from nearby glutamatergic cells (Rec) and puffing solutions (puff, lower panel DIC). Scale bar: 10 Âµm. (<bold>B</bold>) Sample traces showing postsynaptic uIPSC responding to presynaptic action potentials induced by short depolarizing voltage pulse injection (2 ms) to GABAergic neurons. (WT, black line; <italic>App<sup>-/-</sup></italic>, red line). (<bold>C</bold>) Quantification of uIPSC amplitude shows a significant decrease in <italic>App<sup>-/-</sup></italic> mice. (WT, nÂ =Â 18 cells from five mice; <italic>App<sup>-/-</sup></italic>, nÂ =Â 17 cells from five mice). (<bold>D</bold>) Sample traces showing uIPSC recordings responding to injection of paired pulses to presynaptic GABAergic neurons (100 ms interpulse interval, left trace and 150 ms interpulse interval, right trace). (<bold>E</bold>) Quantification of paired pulse ratio (PPR) of uIPSCs with 100 ms and 150 ms interpulse intervals shows no significant difference between genotypes. (<bold>F</bold>) Sample traces showing evoked inhibitory currents responses to puffing 100 ÂµM isoguvacine. (<bold>G</bold>) Quantification of isoguvacine-evoked inhibitory current amplitudes shows a significant decrease in <italic>App<sup>-/-</sup></italic> mice. (WT, nÂ =Â 14 cells from three mice; <italic>App<sup>-/-</sup></italic>, nÂ =Â 14 cells from three mice). (<bold>H</bold>) Representative immunoblots of hippocampal extracts from WT and <italic>App<sup>-/-</sup></italic> littermates. (<bold>I</bold>) Quantification of the immunoblots reveals a significant decrease of GABA<sub>A</sub>R Î±1, but not other GABA<sub>A</sub>R subunits, levels in <italic>App<sup>-/-</sup></italic> mice. Representative immunoblots of western blotting were from single experiment using three pairs hippocampal lysates, two repeats. *p&lt;0.05; Studentâs <italic>t</italic>-test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.005">http://dx.doi.org/10.7554/eLife.20142.005</ext-link></p><p><supplementary-material id="SD1-data"><object-id pub-id-type="doi">10.7554/eLife.20142.006</object-id><label>Figure 2âsource data 1.</label><caption><title>Contains source data for <xref ref-type="fig" rid="fig2">Figure 2</xref> and all accompanying <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplements 1</xref>,<xref ref-type="fig" rid="fig2s2">2</xref>.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.006">http://dx.doi.org/10.7554/eLife.20142.006</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-20142-fig2-data1-v2.xls"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20142-fig2-v2"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20142.007</object-id><label>Figure 2âfigure supplement 1.</label><caption><title>Similar numbers of GABAergic interneurons and mIPSC in WT and <italic>App<sup>-/-</sup></italic> hippocampus.</title><p>(<bold>A</bold>) Images of hippocampal sections from <italic>App<sup>-/-</sup></italic>-<italic>Gad67<sup>+/GFP</sup></italic> and <italic>WT-Gad67<sup>+/GFP</sup></italic> littermates. Scale bar: 400 Âµm; Enlarge: 20 Âµm. (<bold>B</bold>) Quantification shows no difference in the number of GABAergic interneuron between WT and <italic>App<sup>-/-</sup></italic> hippocampus. Each value represents the meanÂ±SEM of at least three sections per genotype, two mice/genotype. (<bold>C</bold>) Sample traces showing mIPSCs from <italic>App<sup>-/-</sup></italic> and WT littermates. (<bold>D</bold>) Quantification of the amplitude and frequency of mIPSCs shows no significant difference between WT and <italic>App<sup>-/-</sup></italic> mice (WT, nÂ =Â 16 cells from three mice; <italic>App<sup>-/-</sup></italic>, nÂ =Â 15 cells from three mice). Studentâs <italic>t</italic>-test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.007">http://dx.doi.org/10.7554/eLife.20142.007</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20142-fig2-figsupp1-v2"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20142.008</object-id><label>Figure 2âfigure supplement 2.</label><caption><title>Identical mEPSC and GluRs levels in between WT and <italic>App<sup>-/-</sup></italic> hippocampus.</title><p>(<bold>A</bold>) Sample traces showing mEPSCs from <italic>App<sup>-/-</sup></italic> and WT littermates. (<bold>B</bold>) Quantification of the amplitude and frequency of mEPSCs shows no significant difference between WT and <italic>App<sup>-/-</sup></italic> mice (WT, nÂ =Â 7 cells from three mice; <italic>App<sup>-/-</sup></italic>, nÂ =Â 9 cells from three mice). (<bold>C</bold>) Representative immunoblots of hippocampal extracts from WT and <italic>App<sup>-/-</sup></italic> littermates. (<bold>D</bold>) Quantification of the immunoblots reveals identical GluR1 and GluR2 levels in between WT and <italic>App<sup>-/-</sup></italic> hippocampus. Representative immunoblots were obtained using three pairs of hippocampal lysates of two independent experiments. Studentâs <italic>t</italic>-test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.008">http://dx.doi.org/10.7554/eLife.20142.008</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20142-fig2-figsupp2-v2"/></fig></fig-group></p></sec><sec id="s2-3"><title>APP deficiency leads to a reduction in total and plasma membrane KCC2 protein levels in hippocampus</title><p>The electrical response of GABA<sub>A</sub>Rs depends on the Cl<sup>-</sup> equilibrium potential. The best characterized effectors of the Cl<sup>-</sup> distribution in the CNS are KCC2 and the Na-K-2Cl cotransporter (NKCC1) (<xref ref-type="bibr" rid="bib1">Ben-Ari, 2002</xref>; <xref ref-type="bibr" rid="bib24">Kaila et al., 2014</xref>; <xref ref-type="bibr" rid="bib30">Lee et al., 2011</xref>; <xref ref-type="bibr" rid="bib35">Rivera et al., 1999</xref>). Since neuronal [Cl<sup>-</sup>]<sub>i</sub> is mainly determined by the opposing activities of the Cl<sup>-</sup> extruding transporter, KCC2, and the Cl<sup>-</sup> importing NKCC1 (<xref ref-type="bibr" rid="bib4">Blaesse et al., 2009</xref>), we compared hippocampal KCC2 and NKCC1 levels in WT and <italic>App<sup>-/-</sup></italic> mice. We found that KCC2, but not NKCC1, protein levels were significantly reduced in <italic>App<sup>-/-</sup></italic> hippocampus compared to WT littermate controls (<xref ref-type="fig" rid="fig3">Figure 3AâB</xref>, <xref ref-type="supplementary-material" rid="SD2-data">Figure 3âsource data 1</xref>). KCC2 is mainly localized to the cell surface (<xref ref-type="bibr" rid="bib17">Gauvain et al., 2011</xref>). To determine whether plasma membrane localization of KCC2 is decreased in APP mutants, we used surface biotinylation in hippocampal tissue (<xref ref-type="fig" rid="fig3">Figure 3A</xref>) or HEK293 cells transfected with KCC2 alone or KCC2 and hAPP695 (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). We observed significantly reduced plasma membrane KCC2 levels in both <italic>App<sup>-/-</sup></italic> hippocampus and HEK293 cells without co-transfection of hAPP695 (<xref ref-type="fig" rid="fig3">Figure 3B and D</xref>, <xref ref-type="supplementary-material" rid="SD2-data">Figure 3âsource data 1</xref>). To examine KCC2 levels in intact tissue, we performed immunohistochemical staining in slice with anti-KCC2 antibody. We observed a selective loss of KCC2 immunoreactivity in <italic>App<sup>-/-</sup></italic> mice in the CA1 region of the hippocampus (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). To determine if this is due to altered transcription of KCC2 in APP mutants, we compared hippocampal KCC2 mRNA levels in <italic>App<sup>-/-</sup></italic> and WT controls. KCC2 mRNA abundance was similar in <italic>App<sup>-/-</sup></italic> and WT hippocampus (<xref ref-type="fig" rid="fig3">Figure 3F</xref>, <xref ref-type="supplementary-material" rid="SD2-data">Figure 3âsource data 1</xref>). Together, these results indicate that APP is required to maintain normal KCC2 protein levels in the hippocampus via a post-transcriptional mechanism.<fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.20142.009</object-id><label>Figure 3.</label><caption><title>Full length APP is required for maintaining normal total and surface KCC2 protein levels.</title><p>(<bold>A</bold>) Representative immunoblots of hippocampal extracts from WT and <italic>App<sup>-/-</sup></italic> littermates. (<bold>B</bold>) Quantification of the immunoblots reveals a significant decrease in surface and total KCC2 protein levels in <italic>App<sup>-/-</sup></italic> mice, while NKCC1 expression levels remain unchanged. Representative immunoblots of western blotting were from single experiment using three pairs of hippocampal lysates, three independent experiments (<bold>C</bold>) Representative immunoblots of HEK293 cells transfected with KCC2 and hAPP695. (<bold>D</bold>) Quantification shows surface and total KCC2 protein levels are elevated when HEK293 cells are transfected with both constructs. (<bold>E</bold>) DAB staining for KCC2 in hippocampal sections from <italic>App<sup>-/-</sup></italic> and WT littermates shows decreased KCC2 levels in CA1 of hippocampus in <italic>App<sup>-/-</sup></italic> mice. Scale bar: 400 Âµm. (<bold>F</bold>) qRT-PCR displays similar KCC2 mRNA levels in WT and <italic>App<sup>-/-</sup></italic> hippocampus. APP mRNA serves as a positive control. Each value represents the meanÂ±SEM of at least three samples per genotype. (<bold>G</bold>) Representative immunoblots of transfected HEK293 cells. (<bold>H</bold>) Quantification of the immunoblots reveals an increase in KCC2 levels when we co-transfect hAPP695, but not when co-transfect with C99 or with sAPPÎ². (<bold>I</bold>) Representative immunoblots of hippocampal extracts from <italic>sAppÎ²Ki</italic> and WT littermates. (<bold>J</bold>) Quantification of the immunoblots reveals a significant decrease of KCC2 protein levels in <italic>sAppÎ²Ki</italic> mice. Representative immunoblots were from single experiment using three pairs of HEK293 cells/ or hippocampal lysates, two repeats. *p&lt;0.05; **p&lt;0.01; **p&lt;0.001; Studentâs <italic>t</italic>-test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.009">http://dx.doi.org/10.7554/eLife.20142.009</ext-link></p><p><supplementary-material id="SD2-data"><object-id pub-id-type="doi">10.7554/eLife.20142.010</object-id><label>Figure 3âsource data 1.</label><caption><title>Contains source data for <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.010">http://dx.doi.org/10.7554/eLife.20142.010</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-20142-fig3-data1-v2.xls"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20142-fig3-v2"/></fig></p></sec><sec id="s2-4"><title>Full length APP stabilizes KCC2</title><p>To determine whether APP could stabilize KCC2 protein, we co-transfected HEK293 cells with KCC2 and hAPP695 cDNAs and assayed subsequent KCC2 protein levels. Cells co-transfected with both constructs displayed higher levels of KCC2 protein compared to cells transfected with only KCC2 (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). APP is proteolytically processed into multiple extracellular and intracellular fragments. We tested these fragments individually to determine which fragment conferred KCC2 stability. We transfected HEK293 cells with KCC2+C99, KCC2+sAPPÎ², or KCC2+hAPP695. Only full length APP but not the intracellular or extracellular fragments of APP prevented KCC2 degradation (<xref ref-type="fig" rid="fig3">Figure 3H</xref>, <xref ref-type="supplementary-material" rid="SD2-data">Figure 3âsource data 1</xref>). Furthermore, using a <italic>sAppÎ²</italic> knock in mouse model (<italic>sAppÎ²Ki</italic>), we observed similarly reduced KCC2 levels in <italic>sAppÎ²Ki</italic> hippocampus compared to WT mice (<xref ref-type="fig" rid="fig3">Figure 3IâJ</xref>, <xref ref-type="supplementary-material" rid="SD2-data">Figure 3âsource data 1</xref>). Together, our results indicate that full length APP is required to maintain normal levels of KCC2 protein.</p></sec><sec id="s2-5"><title>APP and KCC2 physically interact to limit tyrosine phosphorylation and thus degradation of KCC2</title><p>To test whether APP regulates KCC2 through direct protein-protein interaction, we performed immunoprecipitation of KCC2 in HEK293 cells co-transfected with constructs encoding KCC2 and hAPP695. First, Coomassie blue staining was performed in transfected HEK293 cells showing a distribution of all proteins, including APP, pulled down by anti-KCC2 antibody (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref>). Next, APP was detected in anti-KCC2 immunoprecipitates (IP). Similarly, immunoprecipitation of APP co-precipitated KCC2 (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). However, immunoprecipitation of the GABA<sub>A</sub>R Î±1 subunit co-transfected with hAPP695, we did not observe a direct physical interaction between APP and GABA<sub>A</sub>R Î±1 subunit (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Immunoprecipitation of KCC2 using hippocampal lysates co-precipitated APP as well (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Further, the APP-KCC2 interaction result was strengthened by proximity ligation assay (PLA) which would sensitively detect a very close surface interaction between proteins (<xref ref-type="bibr" rid="bib42">SÃ¶derberg et al., 2006</xref>) (<xref ref-type="fig" rid="fig4">Figure 4D</xref>).<fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.20142.011</object-id><label>Figure 4.</label><caption><title>APP interacts with KCC2 to limit KCC2 tyrosine phosphorylation and degradation.</title><p>(<bold>A</bold>) KCC2 interacts with APP in HEK293 cells by co-IP with both KCC2 and APP antibodies. Rabbit IgG (IP: IgG) was used as a negative control. (<bold>B</bold>) GABA<sub>A</sub>R Î±1 subunit does not coimmunoprecipitate with APP. (<bold>C</bold>) KCC2 interacts with APP by co-IP in hippocampal lysates. (<bold>D</bold>) KCC2 interacts with APP by proximity ligation assay (PLA). HEK293 cell was transfected with APP and KCC2, APP alone or KCC2 alone. Red: PLA signal indicates an existence of APP-KCC2 interaction; Blue: DAPI. Scale bar: 20 Âµm. (<bold>E</bold>) Hippocampal extracts from WT and <italic>App<sup>-/-</sup></italic> littermates were immunoprecipitated with an anti-KCC2 antibody (IP: KCC2) and probed with 4G10 antibody (anti-Phospho-tyrosine). Tyrosine phosphorylation of KCC2 is increased in <italic>App<sup>-/-</sup></italic> mice. Total KCC2 levels are also decreased in <italic>App<sup>-/-</sup></italic> mice. (Extracts were from three mice per genotype). (<bold>F</bold>) Representative immunoblots of KCC2 transfected HEK293 cells incubated with PP2 or vehicle. (<bold>G</bold>) Quantification of the immunoblots reveals a significant increase in KCC2 protein levels in PP2 treated HEK293 cells. Representative immunoblots of western blotting were from single experiment using three pairs of HEK293 lysates, two repeats. *p&lt;0.05; Studentâs <italic>t</italic>-test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.011">http://dx.doi.org/10.7554/eLife.20142.011</ext-link></p><p><supplementary-material id="SD3-data"><object-id pub-id-type="doi">10.7554/eLife.20142.012</object-id><label>Figure 4âsource data 1.</label><caption><title>Contains source data for <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.012">http://dx.doi.org/10.7554/eLife.20142.012</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-20142-fig4-data1-v2.xls"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20142-fig4-v2"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20142.013</object-id><label>Figure 4âfigure supplement 1.</label><caption><title>Coomassie-stained SDS-PAGE gel showing KCC2 binding proteins after immunoprecipitated with an anti-KCC2 antibody (IP: KCC2).</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.013">http://dx.doi.org/10.7554/eLife.20142.013</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20142-fig4-figsupp1-v2"/></fig></fig-group></p><p>KCC2 is regulated post-translationally by tyrosine phosphorylation (<xref ref-type="bibr" rid="bib29">Lee et al., 2010</xref>; <xref ref-type="bibr" rid="bib47">Wake et al., 2007</xref>). Increased tyrosine phosphorylation of KCC2 enhances lysozomal degradation and thus decreases KCC2 levels (<xref ref-type="bibr" rid="bib30">Lee et al., 2011</xref>, <xref ref-type="bibr" rid="bib29">2010</xref>). We hypothesized that APP may normally interact with KCC2 to prevent tyrosine phosphorylation and subsequent degradation. To test this hypothesis, we examined whether tyrosine phosphorylated KCC2 levels increased in the absence of APP. Hippocampal tissue from <italic>App<sup>-/-</sup></italic> and WT mice was lysed and immunoprecipitated with anti-KCC2 antibody (<xref ref-type="bibr" rid="bib29">Lee et al., 2010</xref>). Precipitates were blotted for tyrosine phosphorylated proteins using the anti-P-Tyr antibody, 4G10. We observed a robust increase in tyrosine phosphorylated KCC2 levels in APP mutants compared to littermate controls (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Moreover, total KCC2 protein levels remained decreased in <italic>App<sup>-/-</sup></italic> (<xref ref-type="fig" rid="fig4">Figure 4E</xref>) (Relative IOD: WT, 544.86; <italic>App<sup>-/-</sup></italic>, 412.56. hippocampal lysates of three mice per genotype) indicating an increase in tyrosine phosphorylation of KCC2 accompanies the reduction in total KCC2 levels. To further demonstrate that KCC2 instability is due, at least in part, to phosphorylation by a tyrosine kinase in the absence of APP, we tested whether blockade of tyrosine kinases by PP2, a potent inhibitor of Src-family tyrosine kinases (<xref ref-type="bibr" rid="bib3">Bi et al., 2000</xref>; <xref ref-type="bibr" rid="bib28">Lee et al., 2007</xref>), enhances KCC2 protein levels. Treatment of HEK293 cells transfected with KCC2 with PP2 at a concentration of 20 ÂµM for 30 min significantly increased KCC2 levels compared to vehicle controls (<xref ref-type="fig" rid="fig4">Figure 4FâG</xref>, <xref ref-type="supplementary-material" rid="SD3-data">Figure 4âsource data 1</xref>). Together, these results suggest that APP-KCC2 interaction functions, at least in part, to limit tyrosine phosphorylation of KCC2, loss of APP leads to excessive tyrosine phosphorylation and premature degradation of KCC2, resulting in reduced KCC2 protein levels in APP mutants.</p></sec><sec id="s2-6"><title>KCC2 abundance and function can be rescued by CLPs</title><p>Next, we tested whether restoring KCC2 function in APP mutant mice would rescue changes in E<sub>GABA</sub> in hippocampal neurons. Chloride extrusion enhancers, CLP257 and CLP290, have been recently shown to restore Cl<sup>-</sup> extrusion capacity only in neurons with reduced KCC2 activity (<xref ref-type="bibr" rid="bib16">Gagnon et al., 2013</xref>). We incubated hippocampal slices from APP mutant mice with CLP257 at 100 ÂµM for 2 hr, and compared E<sub>GABA</sub> in slices treated with CLP257 or vehicle. Activation of KCC2 in <italic>App<sup>-/-</sup></italic> hippocampus resulted in a hyperpolarizing shift of E<sub>GABA</sub> (CLP257, â66Â Â±Â 3 mV; Control, â54Â Â±Â 2 mV; p=0.03) (<xref ref-type="fig" rid="fig5">Figure 5AâB</xref>, <xref ref-type="supplementary-material" rid="SD4-data">Figure 5âsource data 1</xref>). We next tested whether restoration of Cl<sup>-</sup> extrusion by chronic treatment with CLP290 (<xref ref-type="bibr" rid="bib16">Gagnon et al., 2013</xref>) rescues KCC2 expression levels. CLP290 or vehicle was intraperitoneally injected once daily for seven consecutive days in <italic>App<sup>-/-</sup></italic> mice, and hippocampal KCC2 levels were analyzed by western blotting. We observed a significant increase in KCC2 levels in CLP290 treated animals compared to vehicle treated <italic>App<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig5">Figure 5CâD</xref>, <xref ref-type="supplementary-material" rid="SD4-data">Figure 5âsource data 1</xref>).<fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.20142.014</object-id><label>Figure 5.</label><caption><title>Restoring KCC2 expression and function in <italic>App<sup>-/-</sup></italic> mice rescues hippocampal E<sub>GABA</sub>, GABA<sub>A</sub>R expression and IPSC amplitude.</title><p>(<bold>A</bold>) Sample traces showing perforated patch recording of E<sub>GABA</sub> in CLP257 or vehicle treated <italic>App<sup>-/-</sup></italic> hippocampal slices. Currents were recorded at the indicated holding potentials shown to the left of each trace. (<bold>B</bold>) Quantification of E<sub>GABA</sub> shows a significant hyperpolarizing shift in <italic>App<sup>-/-</sup></italic> in CLP257 treated slices compared to vehicle controls (CLP257, nÂ =Â 5 cells from three mice; Control, nÂ =Â 5 cells from three mice). (<bold>C</bold>) Representative immunoblots of hippocampal extracts from <italic>App<sup>-/-</sup></italic> treated with CLP290 or vehicle. (<bold>D</bold>) Quantification of the immunoblots reveals increased KCC2 protein levels in CLP290 treated <italic>App<sup>-/-</sup></italic> mice. (<bold>E</bold>) Representative immunoblots of HEK293 cells transfected with KCC2 incubated with CLP257 or vehicle. (<bold>F</bold>) Quantification of the immunoblots reveals a significant increase in surface KCC2 protein levels when treated with CLP257, while total KCC2 levels remain unchanged, suggesting CLP257 might regulate KCC2 activity through blocking the latterâs turnover. (<bold>G</bold>) Sample traces of evoked inhibitory currents in response to puffs of 100 ÂµM isoguvacine. (<bold>H</bold>) Quantification of isoguvacine-evoked inhibitory current amplitudes shows a significant increase in CLP257 treated <italic>App<sup>-/-</sup></italic> hippocampus compared to vehicle controls (CLP257, nÂ =Â 15 cells from three mice; Control, nÂ =Â 15 cells from three mice), but no difference between CLP257 treated WT hippocampus and vehicle treated controls (CLP257, nÂ =Â 9 cells from three mice; Control, nÂ =Â 11 cells from three mice), suggesting that restoring KCC2 function rescues GABA<sub>A</sub>R mediated responses. (<bold>I</bold>) Representative immunoblots of hippocampal extracts from <italic>App<sup>-/-</sup></italic> treated with CLP290 or vehicle. (<bold>J</bold>) Quantification of the immunoblots reveals increased GABA<sub>A</sub>R Î±1 protein levels in CLP290 treated <italic>App<sup>-/-</sup></italic> mice. Representative immunoblots of western blotting were from single experiment using three pairs of HEK293 cells/ or hippocampal lysates of two independent experiments. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; Studentâs <italic>t</italic>-test; quantified data of <bold>H</bold>, two-way ANOVA with post hoc tests.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.014">http://dx.doi.org/10.7554/eLife.20142.014</ext-link></p><p><supplementary-material id="SD4-data"><object-id pub-id-type="doi">10.7554/eLife.20142.015</object-id><label>Figure 5âsource data 1.</label><caption><title>Contains source data for <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.015">http://dx.doi.org/10.7554/eLife.20142.015</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-20142-fig5-data1-v2.xls"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20142-fig5-v2"/></fig></p><p>It has been proposed that CLPs might increase KCC2 levels by reducing membrane KCC2 turnover (<xref ref-type="bibr" rid="bib16">Gagnon et al., 2013</xref>). We then examined, in 293 cells transfected with KCC2, if treatment with CLP257 would indeed increase levels of membrane KCC2, and observed significantly enhanced surface KCC2 levels in CLP257 treated cells compared to vehicle control (<xref ref-type="fig" rid="fig5">Figure 5EâF</xref>, <xref ref-type="supplementary-material" rid="SD4-data">Figure 5âsource data 1</xref>). These experiments could not distinguish whether CLP restored KCC2 levels by increasing insertion or decreasing removal of KCC2. Instead, the study suggested a rescue of KCC2 surface levels and function by CLPs in <italic>App<sup>-/-</sup></italic> mice.</p></sec><sec id="s2-7"><title>GABA<sub>A</sub>R Î±1 subunit abundance and GABA<sub>A</sub>R mediated inhibition are dependent on KCC2</title><p>We observed decreases in GABA<sub>A</sub>R Î±1 subunit protein levels and smaller evoked IPSC amplitudes in APP mutants (<xref ref-type="fig" rid="fig2">Figure 2</xref>). We then tested whether potentiating KCC2 function would rescue GABA<sub>A</sub>R mediated inhibitory currents in APP mutant hippocampal slices. Evoked whole-cell inhibitory currents, induced by puffing the GABA<sub>A</sub>R agonist isoguvacine, were recorded after incubation with CLP257 or vehicle for 2 hr, respectively. Evoked inhibitory current amplitudes were significantly larger in CLP257 treated <italic>App<sup>-/-</sup></italic> slices compared to vehicle controls (<italic>App<sup>-/-</sup></italic>: CLP257, 410Â Â±Â 34 pA; Vehicle, 278Â Â±Â 31 pA; p=0.008) (<xref ref-type="fig" rid="fig5">Figure 5GâH</xref>). Importantly, CLP257 treated WT slices did not differ significantly compared to vehicle controls (WT: CLP257, 612Â Â±Â 99 pA; Vehicle, 510Â Â±Â 109 pA; p=0.5) (<xref ref-type="fig" rid="fig5">Figure 5GâH</xref>). Additionally, chronic treatment with CLP290 rescued GABA<sub>A</sub>R Î±1 subunit protein levels as well (<xref ref-type="fig" rid="fig5">Figure 5IâJ</xref>, <xref ref-type="supplementary-material" rid="SD4-data">Figure 5âsource data 1</xref>). These results support a model in which APP loss of function results in reduced KCC2 levels and decreased KCC2 function, which causes the attenuation of GABA<sub>A</sub>R Î±1 expression and GABA<sub>A</sub>R mediated inhibitory current amplitudes, leading to a decrease of inhibitory tone in the hippocampus of APP mutants.</p><p>To test whether GABA<sub>A</sub>R Î±1 level changes are dependent on the presence of KCC2, we transfected HEK293 cells with GABA<sub>A</sub>R Î±1 or Î²2 subunits with and without co-transfection of KCC2. Interestingly, we only observed significantly reduced GABA<sub>A</sub>R Î±1, but not Î²2, subunit levels in the absence of KCC2 (<xref ref-type="fig" rid="fig6">Figure 6AâB</xref>, <xref ref-type="supplementary-material" rid="SD5-data">Figure 6âsource data 1</xref>), suggesting a selective role of KCC2 on GABA<sub>A</sub>R Î±1 expression.<fig-group><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.20142.016</object-id><label>Figure 6.</label><caption><title>GABA<sub>A</sub>R Î±1 subunit is regulated by KCC2 expression through affecting intracellular Cl<sup>-</sup>.</title><p>(<bold>A</bold>) Representative immunoblots of GABA<sub>A</sub>R Î±1+KCC2, GABA<sub>A</sub>R Î±1+pcDNA3, GABA<sub>A</sub>R Î²2+KCC2, GABA<sub>A</sub>R Î²2+pcDNA3, transfected HEK293 cells blotted with anti-GABA<sub>A</sub>R antibodies. (<bold>B</bold>) Quantification of the immunoblots reveals a significant increase in GABA<sub>A</sub>R Î±1 levels in HEK293 cells co-transfected with GABA<sub>A</sub>R Î±1 and KCC2, indicating KCC2 positively regulates expression of GABA<sub>A</sub>R Î±1. (<bold>C</bold>) GABA<sub>A</sub>R-Î±1 does not co-immunoprecipitate with KCC2, suggesting that there was no protein-protein interaction between KCC2 and GABA<sub>A</sub>R Î±1. (<bold>D</bold>) Representative immunoblots of hippocampal extracts from WT and <italic>App<sup>-/-</sup></italic> littermates. (<bold>E</bold>) Quantification of the immunoblots reveals identical PLIC-1 levels in between WT and <italic>App<sup>-/-</sup></italic> hippocampus. (<bold>F</bold>) Representative immunoblots of WT hippocampal slices incubated with a KCC2 inhibitor, VU02450551, or vehicle. (<bold>G</bold>) Representative immunoblots of <italic>App<sup>-/-</sup></italic> hippocampal slices incubated with a KCC2 inhibitor, VU02450551, or vehicle. (<bold>H</bold>) Quantification of the immunoblots reveals a significant decrease only in GABA<sub>A</sub>R Î±1 levels of hippocampal tissue treated with VU02450551. (<bold>I</bold>) Representative immunoblots of hippocampal extracts from P7 and P35 WT mice. (<bold>J</bold>) Quantification of the immunoblots reveals significantly increased KCC2 and GABA<sub>A</sub>R Î±1 levels in P35 compared to P7 WT mice. Representative immunoblots of western blotting were from single experiment using three pairs of HEK293 cells/ or hippocampal lysates, two repeats. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; Studentâs <italic>t</italic>-test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.016">http://dx.doi.org/10.7554/eLife.20142.016</ext-link></p><p><supplementary-material id="SD5-data"><object-id pub-id-type="doi">10.7554/eLife.20142.017</object-id><label>Figure 6âsource data 1.</label><caption><title>Contains source data for <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.017">http://dx.doi.org/10.7554/eLife.20142.017</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-20142-fig6-data1-v2.xls"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20142-fig6-v2"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20142.018</object-id><label>Figure 6âfigure supplement 1.</label><caption><title>Immunofluorescent staining of hippocampal KCC2 in P14 and P35 WT mice shows increased KCC2 levels in P35 WT mice.</title><p>Scale bar: 100 Âµm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.018">http://dx.doi.org/10.7554/eLife.20142.018</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20142-fig6-figsupp1-v2"/></fig></fig-group></p><p>The mechanisms underlying the actions of KCC2 on GABAergic synapses are currently unclear (<xref ref-type="bibr" rid="bib10">Chudotvorova et al., 2005</xref>). We next conducted experiments to elucidate how KCC2 regulates GABA<sub>A</sub>R Î±1 expression and thus GABA<sub>A</sub>R mediated inhibition. During immunoprecipitation of the GABA<sub>A</sub>R Î±1 subunit co-transfected with KCC2, we did not observe a direct physical interaction between KCC2 and GABA<sub>A</sub>R Î±1 subunit (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), indicating that KCC2 regulation of GABA<sub>A</sub>R Î±1 expression was unlikely through a direct protein-protein interaction.</p><p>In a previous report the ubiquitin-like protein PLIC-1, which regulates the membrane trafficking of GABA<sub>A</sub>R, was shown to directly interact with GABA<sub>A</sub>Rs and promote their accumulation at the cell surface (<xref ref-type="bibr" rid="bib36">Saliba et al., 2008</xref>). We next examined if KCC2 regulates GABA<sub>A</sub>R Î±1 levels through affecting PLIC-1 expression, however, Western blotting result showed identical PLIC-1 levels in hippocampus of WT and <italic>App<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig6">Figure 6DâE</xref>, <xref ref-type="supplementary-material" rid="SD5-data">Figure 6âsource data 1</xref>).</p><p>It has been shown that expression of GABA<sub>A</sub>R subunits is regulated by KCC2 expression through affecting intracellular Cl<sup>-</sup> gradient (<xref ref-type="bibr" rid="bib41">Succol et al., 2012</xref>). We thus proposed that KCC2-mediated Cl<sup>-</sup> extrusion might underlie KCC2 regulation of GABA<sub>A</sub>R Î±1 protein levels. If this was the case, treatment of WT hippocampus with a KCC2 inhibitor, VU02450551, would result in a reduction of Î±1 subunit of GABA<sub>A</sub>R protein levels as seen in <italic>App<sup>-/-</sup></italic> hippocampus. Hippocampal GABA<sub>A</sub>R Î±1, several other GABA<sub>A</sub>R subunits and GluRs levels were analyzed by western blotting after incubation with VU02450551 or vehicle for 2 hr in WT hippocampus slices. We observed a significant decrease in GABA<sub>A</sub>R Î±1 levels, but not that of other GABA<sub>A</sub>Rs and GluRs subunits in VU02450551 treated WT hippocampus compared to vehicle control (<xref ref-type="fig" rid="fig6">Figure 6F and H</xref>,Â <xref ref-type="supplementary-material" rid="SD5-data">Figure 6âsource data 1</xref>). Moreover, incubation of <italic>App<sup>-/-</sup></italic> hippocampus with KCC2 inhibitor, VU02450551, further reduced levels of GABA<sub>A</sub>R Î±1 subunit but left GluR1 levels unchanged (<xref ref-type="fig" rid="fig6">Figure 6G and H</xref>, <xref ref-type="supplementary-material" rid="SD5-data">Figure 6âsource data 1</xref>). These experiments suggested that blockade of Cl<sup>-</sup> extrusion by VU02450551 selectively affected levels of GABA<sub>A</sub>R Î±1, but not other GABA<sub>A</sub>R subunits tested in the present study.</p><p>It was well known that the expression of KCC2 and GABAergic inhibition parallel neuronal maturation and the emergence of low intracellular Cl<sup>-</sup> (<xref ref-type="bibr" rid="bib2">Ben-Ari et al., 2012</xref>; <xref ref-type="bibr" rid="bib4">Blaesse et al., 2009</xref>; <xref ref-type="bibr" rid="bib35">Rivera et al., 1999</xref>). KCC2 exports Cl<sup>-</sup> and is weakly expressed at birth and upregulated as the brain matures (<xref ref-type="bibr" rid="bib33">Plotkin et al., 1997</xref>; <xref ref-type="bibr" rid="bib35">Rivera et al., 1999</xref>). To further evaluate the notion that rescue of GABA<sub>A</sub>R Î±1 expression and GABA<sub>A</sub>R mediated inhibition in <italic>App<sup>-/-</sup></italic> hippocampus by restoring KCC2 levels involves alteration in intracellular Cl<sup>-</sup>, we compared hippocampal KCC2 and GABA<sub>A</sub>R Î±1 levels by western blotting in between postnatal day 7 (P7) (with high intracellular Cl<sup>-</sup> concentration) and P35 (with low intracellular Cl<sup>-</sup> concentration) WT mice, and observed significantly increased GABA<sub>A</sub>R and KCC2 levels in P35 compared to P7 hippocampus (<xref ref-type="fig" rid="fig6">Figure 6IâJ</xref>, <xref ref-type="supplementary-material" rid="SD5-data">Figure 6âsource data 1</xref>). Similar to western blotting, immunofluorescent staining in P14 and P35 hippocampus displayed higher KCC2 levels in P35 compared to P14 mice (<xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1</xref>). Data thus far suggested that rescue of GABA<sub>A</sub>R Î±1 levels by restoring KCC2 in <italic>App<sup>-/-</sup></italic> hippocampus involved, at least in part, an alteration of KCC2 mediated Cl<sup>-</sup> extrusion.</p></sec><sec id="s2-8"><title>APP also functions to suppress ubiquitination and thus degradation of KCC2</title><p>Having shown that one way for APP to regulate KCC2 levels was to limit tyrosine phosphorylation and sequential degradation of KCC2, we speculated that blockade of tyrosine phosphorylation of KCC2 by mutating Y903A and Y1087A (mKCC2) which are two tyrosine phosphorylating sites of KCC2 may restore KCC2 levels in the absence of APP. However, mKCC2 levels were significantly lower without hAPP695 than with (<xref ref-type="fig" rid="fig7">Figure 7AâB</xref>, <xref ref-type="supplementary-material" rid="SD6-data">Figure 7âsource data 1</xref>). Meanwhile, mKCC2 levels are identical in PP2 treated and non-treated HEK293 cells (<xref ref-type="fig" rid="fig7">Figure 7CâD</xref>, <xref ref-type="supplementary-material" rid="SD6-data">Figure 7âsource data 1</xref>) confirming that mKCC2 did not undergo tyrosine phosphorylation, which met desired effect. Moreover, both IP and PLA examinations displayed direct protein-protein interaction between APP and mKCC2 (<xref ref-type="fig" rid="fig7">Figure 7EâF</xref>), suggesting that mutation of KCC2 at tyrosine phosphorylating sites did not disturb APP-KCC2 interaction. We then hypothesized that APP deficiency might cause a loss of acting force to hold mKCC2 on site leading to an increase in mKCC2 internalization, resulting in enhanced mKCC2 degradation via an unknown pathway rather than tyrosine phosphorylation. Interestingly, similar to co-transfection of mKCC2 with hAPP695 constructs, HEK293 cells co-transfected with mKCC2 and cylindromatosis (CYLD, a deubiquitinating enzyme) displayed higher levels of mKCC2 protein levels compared to cells transfected with only mKCC2 (<xref ref-type="fig" rid="fig7">Figure 7GâH</xref>, <xref ref-type="supplementary-material" rid="SD6-data">Figure 7âsource data 1</xref>), implicating that mKCC2 might undergo ubiquitination and subsequent degradation in the absence of APP.<fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.20142.019</object-id><label>Figure 7.</label><caption><title>APP interacts with mKCC2 to limit mKCC2 ubiquitination and degradation.</title><p>(<bold>A</bold>) Representative immunoblots of HEK293 cells transfected with mKCC2 and hAPP695. (<bold>B</bold>) KCC2 protein levels are elevated when HEK293 cells are transfected with both constructs. (<bold>C</bold>) Representative immunoblots of mKCC2 transfected HEK293 cells incubated with PP2 or vehicle. (<bold>D</bold>) Quantification of the immunoblots reveals identical KCC2 protein levels in between PP2 treated HEK293 cells and vehicle control. (<bold>E</bold>) mKCC2 interacts with APP. Rabbit IgG (IP: IgG) was used as a negative control. (<bold>F</bold>) PLA shows that mKCC2 interacts with as well. HEK293 cell were transfected with both APP and mKCC2, APP alone, or mKCC2 alone. Red: PLA signal indicates an existence of APP-mKCC2 interaction; Blue: DAPI. Scale bar: 20 Âµm. (<bold>G</bold>) Representative immunoblots of transfected HEK293 cells. (<bold>H</bold>) Quantification of the immunoblots reveals a significantly increased KCC2 protein levels in HEK293 cell transfected with hAPP695 and CYLD, respectively. Representative immunoblots of western blotting were from single experiment using three pairs of lysates, two repeats. **p&lt;0.01; ***p&lt;0.001; Studentâs <italic>t</italic>-test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.019">http://dx.doi.org/10.7554/eLife.20142.019</ext-link></p><p><supplementary-material id="SD6-data"><object-id pub-id-type="doi">10.7554/eLife.20142.020</object-id><label>Figure 7âsource data 1.</label><caption><title>Contains source data for <xref ref-type="fig" rid="fig7">Figure 7</xref>.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.020">http://dx.doi.org/10.7554/eLife.20142.020</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-20142-fig7-data1-v2.xls"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20142-fig7-v2"/></fig></p><p>Next, treating mKCC2 transfected HEK293 cells (in the presence or absence of APP co-transfection) with the ubiquitination inhibitor MG132, we observed that MG132 increased levels of mKCC2 only in the absence (<xref ref-type="fig" rid="fig8">Figure 8A leftâB</xref>, <xref ref-type="supplementary-material" rid="SD7-data">Figure 8âsource data 1</xref>) but not in the presence (<xref ref-type="fig" rid="fig8">Figure 8A rightâB</xref>, <xref ref-type="supplementary-material" rid="SD7-data">Figure 8âsource data 1</xref>) of hAPP695, supporting that APP functions to limit mKCC2 ubiquitination. Moreover, using MG132 to block ubiquitination in HEK293 cells transfected with KCC2, we confirmed that ubiquitination occurred in KCC2 as well in the absence of APP (<xref ref-type="fig" rid="fig8">Figure 8CâD</xref>, <xref ref-type="supplementary-material" rid="SD7-data">Figure 8âsource data 1</xref>).<fig id="fig8" position="float"><object-id pub-id-type="doi">10.7554/eLife.20142.021</object-id><label>Figure 8.</label><caption><title>APP deficiency causes an increase in KCC2 ubiquitination leading to a reduction of KCC2 levels.</title><p>(<bold>A</bold>) Representative immunoblots of HEK293 cells transfected with mKCC2 alone, mKCC2 and hAPP695, incubated with MG132 or vehicle. (<bold>B</bold>) Quantification of the immunoblots reveals a significantly increased mKCC2 levels in HEK293 cell transfected with mKCC2 alone and incubated with MG132. (<bold>C</bold>) Representative immunoblots of HEK293 cells transfected with KCC2 alone (incubated with MG132); KCC2 and hAPP695. (<bold>D</bold>) Quantification of the immunoblots reveals a significantly increased KCC2 protein levels in KCC2 alone with MG132 incubation, which is similar to co-transfection of hAPP695 and KCC2, compared to KCC2 alone incubated with vehicle. (<bold>E</bold>) Representative immunoblots of supernatant before and after IP pull down of KCC2 in WT and <italic>App<sup>-/-</sup></italic> mice. (<bold>F</bold>) Hippocampal extracts from WT and <italic>App<sup>-/-</sup></italic> littermates immunoprecipitated with an anti-KCC2 antibody (IP: KCC2) and probed with ubiquitin antibody. Ubiquitinated KCC2 is obviously increased in <italic>App<sup>-/-</sup></italic> compared to WT mice (Each extract was from three mice per genotype, repeated twice). (<bold>G</bold>) Representative immunoblots of <italic>App<sup>-/-</sup></italic> hippocampus incubated with MG132 or vehicle. (<bold>H</bold>) Quantification of the immunoblots reveals a significantly increased KCC2 protein levels in MG132 treated <italic>App<sup>-/-</sup></italic> hippocampus implicating KCC2 underwent ubiquitination in the absence of APP. (<bold>I</bold>) Representative immunoblots of surface KCC2 levels of HEK293 cells and <italic>App<sup>-/-</sup></italic> hippocampus incubated with MG132 or vehicle. (<bold>J</bold>) Quantification of the immunoblots reveals a significantly increased surface KCC2 levels in MG132 treated compared to vehicle control. Representative immunoblots of western blotting were from single experiment using three pairs of HEK293 cells/ or hippocampal lysates, two repeats. *p&lt;0.05; ***p&lt;0.001; Studentâs <italic>t</italic>-test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.021">http://dx.doi.org/10.7554/eLife.20142.021</ext-link></p><p><supplementary-material id="SD7-data"><object-id pub-id-type="doi">10.7554/eLife.20142.022</object-id><label>Figure 8âsource data 1.</label><caption><title>Contains source data for <xref ref-type="fig" rid="fig8">Figure 8</xref>.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.022">http://dx.doi.org/10.7554/eLife.20142.022</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-20142-fig8-data1-v2.xls"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20142-fig8-v2"/></fig></p><p>We then examined whether KCC2 ubiquitination contributed to reduction of KCC2 levels in <italic>App<sup>-/-</sup></italic> hippocampus. Hippocampal tissue from <italic>App<sup>-/-</sup></italic> and WT mice was lysed and immunoprecipitated with anti-KCC2 antibody. Precipitates were blotted for ubiquitin/ubiquitinated proteins using the anti-ubiquitin antibody. We observed a robust increase in ubiquitinated KCC2 levels in <italic>App<sup>-/-</sup></italic> hippocampus compared to littermate controls (<xref ref-type="fig" rid="fig8">Figure 8EâF</xref>). Furthermore, incubating hippocampus containing <italic>App<sup>-/-</sup></italic> slices with MG132 significantly increased KCC2 levels (<xref ref-type="fig" rid="fig8">Figure 8GâH</xref>, <xref ref-type="supplementary-material" rid="SD7-data">Figure 8âsource data 1</xref>). Moreover, surface KCC2 levels could also be increased by MG132 blockade of KCC2 ubiquitination in HEK293 cells and <italic>App<sup>-/-</sup></italic> hippocampus (<xref ref-type="fig" rid="fig8">Figure 8IâJ</xref>, <xref ref-type="supplementary-material" rid="SD7-data">Figure 8âsource data 1</xref>).</p><p>Data thus far indicated that KCC2 levels could be regulated post-translationally by ubiquitination as well as tyrosine phosphorylation in the absence of APP. APP-KCC2 interaction played a crucial role in suppressing KCC2 internalization and subsequent degradation via both tyrosine phosphorylation and ubiquitination. APP deficiency resulted in a loss of acting force to hold membrane KCC2, leading to enhanced KCC2 degradation in the hippocampus.</p></sec><sec id="s2-9"><title>Restoring KCC2 by CLP257 did not rescue abnormal tonic GABAergic current in CA1 of <italic>App<sup>-/-</sup></italic> mice</title><p>GABA has not only phasic but also tonic mode of action (tonic GABA current) and the latter involves extrasynaptic GABA<sub>A</sub>Rs and/or reactive astrocytic GABA (<xref ref-type="bibr" rid="bib12">Curia et al., 2009</xref>; <xref ref-type="bibr" rid="bib23">Jo et al., 2014</xref>), and tonic GABA action has been implicated in AD mouse models (<xref ref-type="bibr" rid="bib23">Jo et al., 2014</xref>; <xref ref-type="bibr" rid="bib53">Wu et al., 2014</xref>; <xref ref-type="bibr" rid="bib56">Yarishkin et al., 2015</xref>). We have previously shown that tonic GABA currents were impaired in the dentate gyrus (DG) of <italic>App<sup>-/-</sup></italic> mice attributing to abnormal genesis and survival of DG newborn neurons (<xref ref-type="bibr" rid="bib51">Wang et al., 2014b</xref>). We thus evaluated whether abnormal tonic GABA currents also occurred in APP deficient CA1 and, observed significantly reduced amplitude of tonic GABA current in the CA1 of <italic>App<sup>-/-</sup></italic> mice compared to WT controls (WT, 19.1Â Â±Â 2.7 pA; <italic>App<sup>-/-</sup></italic>, 9.1Â Â±Â 0.7 pA; p=0.002) (<xref ref-type="supplementary-material" rid="SD8-data">Figure 9âsource data 1</xref>). Interestingly, restoring KCC2 by CLP257 incubation of <italic>App<sup>-/-</sup></italic> hippocampal slice did not rescue impaired tonic GABA current (<italic>App<sup>-/-</sup></italic>, 9.1Â Â±Â 0.7 pA; <italic>App<sup>-/-</sup></italic>+CLP257, 11.9Â Â±Â 1.6 pA; p=0.1) (<xref ref-type="supplementary-material" rid="SD8-data">Figure 9âsource data 1</xref>), suggesting that aberrant KCC2 levels and function might underlie impaired phasic but not tonic GABA current in the CA1 of <italic>App<sup>-/-</sup></italic> mice.<fig id="fig9" position="float"><object-id pub-id-type="doi">10.7554/eLife.20142.023</object-id><label>Figure 9.</label><caption><title>Reduced tonic GABA current in CA1 of <italic>App<sup>-/-</sup></italic> hippocampus.</title><p>(<bold>A</bold>) Sample traces of tonic GABA current in WT, <italic>App<sup>-/-</sup></italic> and <italic>App<sup>-/-</sup></italic> incubated with 100 Î¼M CLP257. (<bold>B</bold>) Quantification of tonic GABA current amplitude shows a significant decrease in <italic>App<sup>-/-</sup></italic> mice and CLP does not rescue tonic GABA current in <italic>App<sup>-/-</sup></italic> hippocampus (WT, nÂ =Â 10 cells from five mice; <italic>App<sup>-/-</sup></italic>, nÂ =Â 10 cells from five mice; <italic>App<sup>-/-</sup></italic>+CLP257, nÂ =Â 9 cells from five mice). *p&lt;0.05; **p&lt;0.01; one-way ANOVA.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.023">http://dx.doi.org/10.7554/eLife.20142.023</ext-link></p><p><supplementary-material id="SD8-data"><object-id pub-id-type="doi">10.7554/eLife.20142.024</object-id><label>Figure 9âsource data 1.</label><caption><title>Contains source data for <xref ref-type="fig" rid="fig9">Figure 9</xref>.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.024">http://dx.doi.org/10.7554/eLife.20142.024</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-20142-fig9-data1-v2.xls"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20142-fig9-v2"/></fig></p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we demonstrate that APP regulation of KCC2 expression and function is required to maintain appropriate GABAergic signaling capacity in the hippocampus as summarized in <xref ref-type="fig" rid="fig10">Figure 10</xref>. This is supported by several lines of evidence: (1) APP deficiency results in a depolarizing shift of E<sub>GABA</sub> along with reduced amplitude of uIPSCs and tonic GABA current, (2) APP deficiency results in a significant reduction in the abundance of hippocampal KCC2, but not NKCC1, and GABA<sub>A</sub>R Î±1 subunit expression, (3) Phasic GABAergic signaling phenotypes can be rescued by CLPs enhancing KCC2 expression and function, suggesting that impaired regulation of KCC2 by APP is responsible for these fast inhibition deficits in APP mutants, while altered tonic GABA current might involve different mechanisms (<xref ref-type="bibr" rid="bib23">Jo et al., 2014</xref>; <xref ref-type="bibr" rid="bib53">Wu et al., 2014</xref>). Together, these data indicate that regulation of KCC2 by APP plays a critical role in the maintenance of normal hippocampal GABAergic inhibition. Identical mIPSC amplitude in between WT and <italic>App<sup>-/-</sup></italic> hippocampus indicates that reduction in GABA<sub>A</sub>R Î±1 expression in <italic>App<sup>-/-</sup></italic> does not impair basal inhibitory activity that requires activation of a portion of GABA<sub>A</sub>R, which is commonly observed when correlating altered receptors with miniature activities (<xref ref-type="bibr" rid="bib8">Caraiscos et al., 2004</xref>; <xref ref-type="bibr" rid="bib10">Chudotvorova et al., 2005</xref>).<fig id="fig10" position="float"><object-id pub-id-type="doi">10.7554/eLife.20142.025</object-id><label>Figure 10.</label><caption><title>A working model shows the mechanism underlying APP regulation of GABA<sub>A</sub>R mediated inhibition.</title><p>KCC2 transports Cl<sup>-</sup> outside the neuron maintaining low [Cl<sup>-</sup>]<sub>i</sub> in mature neurons and therefore insures an Cl<sup>-</sup> influx upon GABA binding to the GABA<sub>A</sub>Rs. APP and KCC2 physically interacts to limit tyrosine phosphorylation, ubiquitination and sequential degradation of KCC2 to maintain abundant membrane KCC2 levels and hyperpolarizing E<sub>GABA</sub> in WT hippocampal neuron. APP deficiency leads to a loss of limit on tyrosine phosphorylation and ubiquitination of KCC2 and thus reduces KCC2 protein levels, resulting in depolarizing shift of E<sub>GABA</sub>, reduction of GABA<sub>A</sub>R Î±1 and GABA mediated inhibition, which can be rescued by restoration of KCC2 expression and function.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20142.025">http://dx.doi.org/10.7554/eLife.20142.025</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20142-fig10-v2"/></fig></p><p>In previous studies, we have shown that impaired GABAergic short-term plasticity evaluated by abnormal PPR of IPSCs is due, in part, to presynaptic alterations of L-type calcium channels (LTCCs) (<xref ref-type="bibr" rid="bib55">Yang et al., 2009</xref>). However, we did not see changes in the PPR of uIPSCs in the present study. This may be due to the fact that IPSCs were induced by field stimulation in previous study, which activates multiple presynaptic GABAergic neurons, and corresponding LTCC currents. By contrast, in the present study, uIPSCs were evoked by a single presynaptic action potential in a single GABAergic neuron such that the involvement of presynaptic LTCCs is minimized. This system allowed us to focus on postsynaptic KCC2 dysfunction in APP mutant hippocampal neurons.</p><p>KCC2 is the principle mechanism used by neurons to lower internal [Cl<sup>-</sup>] which is required for adequate inhibitory synaptic transmission upon activation of GABA<sub>A</sub>Rs and GlyRs (<xref ref-type="bibr" rid="bib6">Braat and Kooy, 2015a</xref>; <xref ref-type="bibr" rid="bib24">Kaila et al., 2014</xref>; <xref ref-type="bibr" rid="bib35">Rivera et al., 1999</xref>). However, little is known about what regulates KCC2 expression and function. In an attempt to understand why KCC2 levels are diminished in APP mutants, we discovered a physical interaction between APP and KCC2. This interaction protects KCC2 from protein phosphorylation and ubiquitination which target the protein for degradation. These results suggest that APP is a novel protein binding-partner for KCC2. APP holds KCC2 on membrane through protein-protein interaction to maintain appropriate KCC2 levels, internal Cl<sup>-</sup> and GABA<sub>A</sub>R mediated inhibition. Though increased activation of glutamatergic receptors has been shown to downregulate KCC2 expression and GABA<sub>A</sub>R mediated current (<xref ref-type="bibr" rid="bib30">Lee et al., 2011</xref>), neither amplitude, frequency of mEPSCs (Amplitude; WT, 13.3Â Â±Â 0.4 pA; <italic>App<sup>-/-</sup></italic>, 12.6Â Â±Â 0.8 pA; p=0.5; Frequency; WT, 0.2Â Â±Â 0.05 Hz; <italic>App<sup>-/-</sup></italic> 0.4Â Â±Â 0.2 Hz; p=0.3) nor GluRs protein levels changed in hippocampus of APP mutants compared to WT controls (<xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 2AâD</xref>, <xref ref-type="supplementary-material" rid="SD1-data">Figure 2âsource data 1</xref>). The results suggest that excitatory synaptic activity mediated by AMPA receptors may not be affected by loss of APP at the age tested.</p><p>Changes in KCC2 levels that occur in APP mutants can have wide ranging effects on the status of GABAergic signaling. Modulation of KCC2 protein levels has been reported to affect GABA<sub>A</sub>R density and GABAergic inhibition (<xref ref-type="bibr" rid="bib10">Chudotvorova et al., 2005</xref>; <xref ref-type="bibr" rid="bib41">Succol et al., 2012</xref>). Therefore, we postulated that altered KCC2 function in APP mutants accounts for changes in GABAergic signaling. To test this, we pharmacologically enhanced KCC2 function in <italic>App<sup>-/-</sup></italic> mice and observed a rescue in both amplitudes of isoguvacine induced currents and GABA<sub>A</sub>R Î±1 expression levels, indicating a rescue of GABAergic functional deficits by restoring KCC2 function. Moreover, we show that blockade of KCC2 mediated Cl<sup>-</sup> extrusion in WT hippocampus resulted in a reduction of GABA<sub>A</sub>R Î±1 levels as seen in <italic>App<sup>-/-</sup></italic> mice and, GABA<sub>A</sub>R Î±1 levels are positively correlated with KCC2 expression and function during early stage of development. We thus reasoned that increase in KCC2 mediated Cl<sup>-</sup> extrusion might be responsible for upregulation of surface GABA<sub>A</sub>R Î±1 levels.</p><p>Though the exact mechanism underlying how restoring KCC2 rescued surface GABA<sub>A</sub>R Î±1 levels remains unclear, given that APP interacts directly with KCC2, and increasing KCC2 expression and function rescued GABAergic signaling phenotypes in <italic>App<sup>-/-</sup></italic> hippocampus, we propose that KCC2 is the primary defect caused by APP deletion to alter GABAergic signaling, while changes in GABA<sub>A</sub>R Î±1 levels and GABA<sub>A</sub>R mediated inhibition are secondary to altered KCC2 expression and function.</p><p>Our results indicate that full length APP is required to maintain normal levels of KCC2 protein. Together with a recent study of the <italic>App</italic>ÎCT15-DM mice, a mouse model lacking the last 15 amino acids of APP as well as the APP homologue, APLP2, which demonstrated impairments of synaptic plasticity and hippocampal-dependent behavior (<xref ref-type="bibr" rid="bib27">Klevanski et al., 2015</xref>), it is likely that APP proteolysis may be a mechanism for turning off normal APP functions which needs to be taken into account when exploring the pathophysiology of APP with respect to KCC2 regulation.</p><p>GABAergic signaling has been shown to be disrupted in many diseases of the nervous system (<xref ref-type="bibr" rid="bib6">Braat and Kooy, 2015a</xref>), including fragile X syndrome and autism spectrum disorder (<xref ref-type="bibr" rid="bib7">Braat and Kooy, 2015b</xref>; <xref ref-type="bibr" rid="bib20">Han et al., 2014</xref>). Changes in KCC2 function may account for many GABAergic signaling deficits, as it has been shown to be involved in the pathogenesis of epilepsy, schizophrenia, autism and aging brain (<xref ref-type="bibr" rid="bib2">Ben-Ari et al., 2012</xref>; <xref ref-type="bibr" rid="bib14">Ferando et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Tang et al., 2016</xref>; <xref ref-type="bibr" rid="bib45">Tao et al., 2012</xref>). Though the GABAergic system appears to be resistant to AÎ² toxicity (<xref ref-type="bibr" rid="bib40">Selkoe, 2002</xref>), recent research has demonstrated dysfunctional GABAergic inhibition in AD (<xref ref-type="bibr" rid="bib46">Verret et al., 2012</xref>). In the present study, we have described a cellular mechanism by which loss of APP function downregulates KCC2 to impair GABAergic signaling. Given the results presented here in APP mutant hippocampal neurons, if APP function is compromised in the context of progressing AD, this may lead to the gradual loss of GABAergic signaling capacity in the hippocampus and associated changes in memory function. Together with a most recent study revealing a critical role of KCC2 in information storage in aging brain (<xref ref-type="bibr" rid="bib14">Ferando et al., 2016</xref>), the present study suggests that KCC2 might serve as a therapeutic target to improve GABAergic inhibition to potentially restore hippocampal function and improve memory in AD.</p></sec><sec id="s4" sec-type="materials|methods"><title>MaterialsÂ andÂ methods</title><sec id="s4-1"><title>Animals and plasmids</title><p>All experiments and animal housing were in accordance with procedures approved by the Ethics Committee for animal research at South China Normal University, according to the Guidelines for Animal Care established by the National Institute of Health. Both female and male mice were used in this study. <italic>App<sup>-/-</sup></italic> and wild type (WT) mice (<xref ref-type="bibr" rid="bib57">Zheng et al., 1995</xref>) were generated by crossing <italic>App<sup>+/-</sup></italic> males and females obtained from Model Animal Research Center of Nanjing University (Nanjing, China). <italic>App<sup>-/-</sup></italic> mice were crossed with <italic>Gad67<sup>+/GFP</sup></italic> mice (<xref ref-type="bibr" rid="bib43">Tamamaki et al., 2003</xref>) (gift from Dr. Yuqiang Ding at Tongji University School of Medicine, Shanghai, China) when necessary to generate <italic>App<sup>-/-</sup></italic>-<italic>Gad67<sup>+/GFP</sup></italic> and <italic>WT-Gad67<sup>+/GFP</sup></italic> controls. Soluble APP ectodomain beta (<italic>sAppÎ²</italic>) knock in mice (<xref ref-type="bibr" rid="bib31">Li et al., 2010</xref>), full length human APP (hAPP695), APP C-terminal fragments (C99) and sAPPÎ² constructs were from Hui Zheng lab at Baylor College of Medicine. The KCC2 construct was gift from John A Payne (School of Medicine, University of California). The GABA<sub>A</sub>R Î±1 construct was gift from Gangyi Wu (South China Normal University, Guangzhou, China). CYLD construct was gift from Shaocong Sun (University of Texas MD Anderson Cancer Center, Texas, USA). GABA<sub>A</sub>R Î²2 construct was from Yong Zhang (Peking University).</p></sec><sec id="s4-2"><title>Neuronal culture</title><p>Cultured hippocampal neurons were prepared as described (<xref ref-type="bibr" rid="bib55">Yang et al., 2009</xref>) with some modifications. Briefly, we dissected hippocampus from <italic>App<sup>-/-</sup></italic>-<italic>Gad67<sup>+/GFP</sup></italic> and <italic>WT-Gad67<sup>+/GFP</sup></italic> littermates of P0/1 pups, trypsinized the tissue at 37Â°C for 30 min, and then gently triturated in culture medium containing 10% heat-inactivated fetal bovine serum using fire-polished pipettes, before centrifuging at 1000 rpm for 10 min. Cells were resuspended in Neurobasal Medium supplemented with B27 and L-glutamine (Invitrogen,Â Carlsbad, CA), and plated at 1â2Â ÃÂ 10<sup>4</sup> cells/ml onto 13 mm poly-L-lysine coated coverslips. One day after plating, 4 M cytosine-D-arabinofuranoside (Ara-C) (Sigma) was added to prevent astrocyte proliferation. Cultures of 12â14 DIV were used for patch clamp recordings.</p></sec><sec id="s4-3"><title>Electrophysiology</title><sec id="s4-3-1"><title>Whole-cell recording in acute hippocampal slices</title><p>Hippocampal slices (350 Î¼m thick) were cut using a vibratome (LeicaVT1000S) in ice-cold cutting solution containing the following: 25 mM NaHCO<sub>3</sub>, 2.5 mM KCl, 7 mM MgCl<sub>2</sub>, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 7 mM Glucose, 0.5 mM CaCl<sub>2</sub>, 115 mM Choline Cl. Slices were incubated for 45 min in artificial cerebrospinal fluid (aCSF) solution containing the following: 119 mM NaCl, 2.5 mM KCl, 2.5 mM CaCl<sub>2</sub>, 1.3 mM MgSO<sub>4</sub>, 1 mM NaH<sub>2</sub>PO<sub>4</sub>, 11 mM D-glucose, 26.2 mM NaHCO<sub>3</sub>. Pipettes were filled with an internal solution of 136.5 mM K-Gluconic acid, 17.5 mM KCl, 9 mM NaCl, 1 mM MgCl<sub>2</sub>, 0.2 mM EGTA, 10 mM HEPES (pH 7.3) containing gramicidin A 10 Î¼g/ml (Sigma; diluted from a stock solution of 10 mg/ml in DMSO). The recording aCSF contains: 140 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl<sub>2</sub>, 1.2 mM MgCl<sub>2</sub>, 11 mM D-glucose, 10 mM HEPES (pH 7.3). Both incubating and recording solutions were bubbled with 95% O<sub>2</sub> and 5% CO<sub>2</sub> throughout the experiment. We performed all the experiments for the determination of E<sub>GABA</sub> values in the presence of TTX (1 Î¼M), CNQX (20 Î¼M), APV (50 Î¼M) and Strychnine (1 Î¼M) to block voltage-gated sodium channels, AMPA receptors, NMDA receptors, and GlyRs, respectively. A Picospritzer (Parker Instrumentation) was used to eject GABA (100 Î¼M, 100 ms) directly onto neuronal soma through a fine pipette (~2 Î¼m tip). For mEPSC and mIPSC recordings, the aCSF was supplemented with 1 Î¼M TTX, and pipettes were filled with an internal solution of 100 mM Cs gluconate, 5 mM CsCl, 10 mM HEPES, 2 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 11 mM BAPTA, 4 mM ATP, 0.4 mM GTP. To record tonic GABA current, 10 Î¼M CNQX and 50 Î¼M APV were added into the aCSF to block glutamate receptors. The total tonic GABA current was revealed by the change of holding current after perfusion of 100 Î¼M bicucullin (Bic). Pipettes were filled with an internal solution of 135 mM CsCl, 5 mM Na-phosphocreatine, 10 mM HEPES, 5 mM EGTA, 4 mM MgATP, 5 mM QX-314 and 0.5 mM Na<sub>2</sub>GTP (pH 7.3) (<xref ref-type="bibr" rid="bib53">Wu et al., 2014</xref>). Data were filtered during acquisition with a low pass filter set at 2 kHz using pClamp10 (Molecular Devices). Data analysis was performed offline with Clampfit 10.2 (Molecular Devices).</p></sec><sec id="s4-3-2"><title>Whole-cell recording in hippocampal cultures</title><p>GABA reversal potential recordings were made using a perforated patch-clamp technique. Pipettes were filled with an internal solution of 140 mM KCl and 10 mM HEPES (pH 7.3) containing gramicidin A 50 Î¼g/ml (Sigma; diluted from a stock solution of 50 mg/ml in DMSO). Data were filtered during acquisition with a low pass filter set at 2 kHz using pClamp10 (Molecular Devices). Data analysis was performed offline with Clampfit 10.2 (Molecular Devices).</p></sec><sec id="s4-3-3"><title>Dual whole-cell patch-clamp recordings</title><p>The culture coverslips were transferred into a heated (30Â°C) submerged recording chamber, continuously perfused (2â3 ml/min) with tyrode buffer: 129 mM NaCl, 5 mM KCl, 0.01 mM Glycine, 1 mM MgCl<sub>2</sub>, 2 mM CaCl<sub>2</sub>, 25 mM HEPES, 30 mM D-Glucose. We performed all experiments for the determination of unitary inhibitory postsynaptic current (uIPSC), and paired-pulse ratio (PPR, uIPSC2/uIPSC1) values in the presence of CNQX (20 Î¼M) and APV (50 Î¼M) to block AMPA receptors and NMDA receptors, respectively. GABAergic neurons were patched in whole-cell, current-clamp configuration using an Axopatch 700B amplifier (Axon Instruments) Channel 1. The pipette solution contained 110 mM K-Gluconic acid, 10 mM NaCl, 1 mM MgCl<sub>2</sub>, 10 mM EGTA, 40 mM HEPES, 2 mM ATP, 0.3 mM GTP (pH adjusted to 7.2 with NaOH). Pyramidal neurons were patched in voltage-clamp configuration and recorded at a holding potential of â60 mV using an Axopatch 700B amplifier (Axon Instruments) Channel 2. The pipette solution contained 100 mM Cesium Methanesulfonate, 10 mM NaCl, 10 mM TEA-Cl, 1 mM MgCl<sub>2</sub>, 10 mM EGTA, 40 mM HEPES, 2 mM ATP, 0.3 mM GTP, 4 mM QX-314 (pH adjusted to 7.2 with NaOH). Before uIPSC recordings, voltage responses of presynaptic and postsynaptic cells were recorded by applying long hyperpolarizing and depolarizing current pulse (300 ms) injections to examine basic electrophysiological properties, including input resistance, single spike kinetics, voltage-current relationships, repetitive firing patterns, and firing frequency. For evoked GABA current recording, a Picospritzer (Parker Instrumentation) was used to eject isoguvacine (100 Î¼M, 100 ms) directly onto neuronal soma through a fine pipette (~2 Î¼m tip).</p></sec></sec><sec id="s4-4"><title>Quantitative Real-time PCR (qRT-PCR)</title><p>Mice brains were dissected and immediately frozen in liquid nitrogen. Total RNA was extracted using Trizol reagent. RNA pellets were resuspended in diethylpyrocarbonate-treated water and RNA concentration was measured using a Nanodrop2000c spectrometer (Thermo Scientific). RNA was DNase treated (DNase I, amplification grade, Invitrogen) and then reverse-transcribed using the Superscript III First-Strand Synthesis System (Invitrogen). Relative quantification of gene expression was performed using Taq Manprobes and an ABI Prism 7000 Sequence Detection System. Platinum Quantitative PCR Super Mix-UDG w/ROX (Invitrogen) was used with the following primers and probes: <italic>App</italic> F-primer, (5ââ3â) CCAAGAGGTCTACCCTGAACTGC; <italic>App</italic> R-primer, (5ââ3â) AGGCAACGGTAAGGAATCACG; <italic>ActÎ²</italic> F-primer (5ââ3â) GTGACGTTGACATCCGTAAAGA; <italic>ActÎ²</italic> R-primer (5ââ3â) GTAACAGTCCGCCTAGAAGCAC; <italic>Slc12a5</italic> F-primer (5ââ3â) GGGCAGAGAGTACGATGGC; <italic>Slc12a5</italic> R-primer (5ââ3â) TGGGGTAGGTTGGTGTAGTTG. Assay efficiencies were experimentally determined using a five-point dilution series of cDNA spanning a 100-fold range in concentration. 0.025 Âµg cDNA template was used per reaction. Statistical analysis was performed on 2<sup>-ââCt</sup> values.</p></sec><sec id="s4-5"><title>Immunohistochemistry</title><p>Mice were anesthetized with intraperitoneal injection of 20% urethane (0.01 ml/g) and perfused transcardially with 0.9% physiological saline and 4% paraformaldehyde (PFA) in phosphate buffer (0.01 M PBS, pH 7.4). Following perfusion, the brains were dissected and post-fixed overnight in 4% PFA followed by a sucrose series (10%, 20% and 30%) solution at 4Â°C for cryoprotection. Serial coronal/sagittal sections of tissue were obtained using Lycra frozen slicer 1800 with a thickness of 30 Î¼m. Free-floating sections were rinsed in PBS three times for 5 min and processed for antigen retrieval by boiling in 10 mM citrate buffer (pH 6.0) for 5 min. The sections were incubated in 3% H<sub>2</sub>O<sub>2</sub> in PBS for 15 min at room temperature (RT) to quench endogenous peroxidases, washed three times for 5 min and subsequently incubated in 0.3% Triton X-100 in PBS for 2 hr. To block nonspecific binding, sections were incubated in 3% bovine serum albumin (BSA) for 30 min. Sections were then incubated overnight with primary antibody against KCC2 (Neuromab, 75â013; Millipore, 07â432) at 4Â°C. After three washes with PBS, secondary antibody (CWS) application was performed at RT for 2 hr followed by three additional washes with PBS for 10 min. The secondary antigen was visualized with 3,3-diaminobenzidine tetrahydrochloride (DAB, Sola). The reaction was terminated by rinsing in PBS and then sections were mounted on gelatin-subbed slides, dehydrated in ascending alcohol concentrations, cleared through xylenes, and covered with DPX resin. KCC2 immunofluorescent staining was conducted as described (<xref ref-type="bibr" rid="bib55">Yang et al., 2009</xref>).</p></sec><sec id="s4-6"><title>Western blotting</title><p>Mouse brains were homogenized using SDS lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA pH 8.0, 1% SDS) containing complete protease inhibitor cocktail (Roche). After 1 min of homogenization, the cellular debris was removed by centrifugation at 14000 rpm for 10 min at 4Â°C and supernatant was collected and denatured for 20 min at 75Â°C. Tissue lysates were subjected to SDS-PAGE (Bio-Rad) and transferred to nitrocellulose membranes. Membranes were blocked for 0.5 hr using 5% non-fat dry milk in TBS containing 0.5% Tween-20 (TBST), then incubated with specific primary antibodies against KCC2 (Neuromab, 75â013; Millipore, 07â432; Santa Cruz, sc-19419), NKCC1 (Abcam, ab191289), APP (Abcam, ab15272), 4G10 (Millipore, 16â452), PLIC-1 (ABGENT, AP2176c), GABA<sub>A</sub>R subunits: Î±1 (Millipore, 06â868), Î±5 (Abcam, ab175195), Î²2 (Abcam, ab156000), Î´ (Abcam, ab110014), Î³2 (Abcam, ab87328), GluR1 subunit (Abcam, ab31232) and GluR2 subunit (Abcam, ab206293) of AMPA receptors, and ubiquitin (Abcam, ab7254). Anti Î³-tubulin antibody (Sigma, T6557) was used as a loading control. Antibodies were diluted at 1:1000 to 1:2000 at use. After three washes with TBST, secondary antibody (CWS) application was performed at RT for 1 hr using 5% milk in TBST followed by three additional washes with TBST. Bands were visualized using Immobilon Western ECL system and analyzed with Gel Pro Analysis software. For surface KCC2 detection, biotinylation of cell surface proteins was performed as described previously (<xref ref-type="bibr" rid="bib29">Lee et al., 2010</xref>). Briefly, HEK293 cells transfected with KCC2 constructs or cultured neurons were washed two times with PBS containing 0.5 mM MgCl<sub>2</sub> and 1 mM CaCl<sub>2</sub> (PBS-CM) and then incubated with 2 ml of PBS-CM containing 1 mg/ml Sulfo-NHS-SS-Biotin (Pierce) for 30 min at 4Â°C. After labeling, the biotin reaction was quenched by washing three times with ice-cold PBS-CM containing 50 mM glycine and 0.1% BSA. Cells were then lyzed with 1 ml lysis buffer and the lysate was collected. Protein concentration was determined using Micro BCA protein assay kit (Thermo Scientific). After correction for protein concentration, 40 Î¼l of 1:1 slurry of UltraLink NeutrAvidin (Pierce) was added to the lysates to pull down the biotin-labeled surface proteins for 2 hr at 4Â°C. The NeutrAvidin beads were washed and bound materials were analyzed by SDS-PAGE.</p></sec><sec id="s4-7"><title>Molecular cloning</title><p>To obtain a KCC2 plasmid in which the tyrosine phosphorylating sites, Y903A and Y1087A, were mutated (mKCC2), the KCC2 open reading frame (ORF) was amplified from the pCAGIG vector, incorporate Y903A and Y1087A mutation using the stratagene QuickChange method as described (<xref ref-type="bibr" rid="bib29">Lee et al., 2010</xref>). For mutation of Y903 the following primers were used: (sense) TCCGGATCCACTCGAGATGCTCAAC; (antisense) AATGTCTTCTCGAAGGTG TATGCTG. For mutation of Y1087 the following primers were used: (sense) TACACCTTCGAGAAGACATTGG; (antisense): ATTTACGTAG CGGCCGCTCAGGAGT AGATGGATATCTGCAGAATTCCATGAAGTTTTCATCTCC.</p></sec><sec id="s4-8"><title>Transfection</title><p>Commercially-available HEK293 cells, original transformated as reported (<xref ref-type="bibr" rid="bib19">Graham et al., 1977</xref>), were co-transfected with KCC2 and GABA<sub>A</sub>R Î±1 or Î²2; KCC2 and APP/ or different APP fragments. Whenever necessary, KCC2 was replaced by mKCC2. Transfected HEK293 cells were washed with ice-cold PBS, centrifuged at 5000 rpm for 10 min at 4Â°C, and the precipitate was collected and homogenized using SDS lysis buffer, centrifuged at 14,000 rpm for 10 min at 4Â°C and supernatant and denatured for 20 min at 75Â°C. Supernatants were analyzed by western blotting.</p></sec><sec id="s4-9"><title>Co-immunoprecipitation (Co-IP)</title><p>HEK293 cells were grown in DMEM (high glucose with L-glutamine) containing 10% FBS. For immunoprecipitation, HEK293 cells were plated onto 10 cm culture dishes, and grown to 70% confluency. Cell transfections were performed with lipofectamine 2000 (Invitrogen), following the manufacturerâs recommended protocol. 24â48 hr after transfection, cells were washed once with cold PBS then homogenized with 1 ml cold lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP40, and protease inhibitor) in 2 ml tubes. To remove cell debris, lysates were centrifuged for 20 min at 14,000 rpm at 4Â°C. Supernatants were incubated with 2 Î¼l of KCC2 (Millipore, 07â432), APPc (<xref ref-type="bibr" rid="bib48">Wang et al., 2007</xref>), or GABA<sub>A</sub>R Î±1 (Millipore, 06â868), antibodies at 4Â°C overnight. Protein A agarose beads at 30 Î¼l (Millipore) was added to each sample and they were incubated at 4Â°C for 2â3 hr. To control for nonspecific binding, protein lysates incubated with rabbit or mouse IgG and beads were processed in parallel. Subsequently, beads were washed three times with 500 Î¼l of cold lysis buffer. Immunoprecipitates were eluted from the beads by adding 30 Î¼l of SDS-PAGE sample buffer and heating for 20 min at 75Â°C. The eluates (15 Î¼l) were analyzed by western blotting. For hippocampal lysates immunoprecipitation, we followed the HEK293 cells protocol above. Coomassie blue staining was conducted as described (<xref ref-type="bibr" rid="bib37">Savas et al., 2015</xref>).</p></sec><sec id="s4-10"><title>Proximity ligation assay (PLA)</title><p>HEK293 cells were grown in DMEM containing 10% FBS. For PLA (<xref ref-type="bibr" rid="bib42">SÃ¶derberg et al., 2006</xref>), HEK293 cells were plated onto 10 cm culture dishes, and grown to 70% confluency. On the day of experiment, the wells were washed with 1xPBS and then added with 4% PFA and incubated for 10 min at RT without agitation. Then the cells were washed with PBS for 3Â times,Â 5 min each,Â with agitation and treated with 0.5% Triton X-100 in PBS (PBST) for 10 min without agitation. Wash the cells with TBST for 3Â times,Â 5 min each,Â with agitation. Block with Duolink II Blocking Solution (1x) for 1 hr at 37Â°C and then incubate with specific primary antibodies against KCC2 (Neuromab, 75â013) or APP (Abcam, ab15272). After wash with 1x Duolink II Wash Buffer A, cells were incubated with two PLA probes (Duolink II anti-Mouse MINUS and Duolink II anti-Rabbit PLUS) 1:5 in Antibody Diluent. Wash the slides in 1x Wash Buffer A for 2 times, 5 min each, with agitation at RT. Incubate the slides with Ligation-Ligase solution for 30 min at 37Â°C. Wash the slides in 1x Wash Buffer A with for 2 times, 2 min each. Then incubate the slides with Amplification-Polymerase solution for 100 min at 37Â°C. Wash the slides for 2 times, 10 min each, in 1x Duolink II Wash Buffer B and incubate with DAPI for 15 min at 37Â°C. Data was analyzed with a fluorescence microscope.</p></sec><sec id="s4-11"><title>KCC2 restoration experiment</title><p>KCC2 enhancers, CLP257 and CLP290 (<xref ref-type="bibr" rid="bib16">Gagnon et al., 2013</xref>) were gifts from Yves De Koninck (Institut universitaire en santÃ© mentale de QuÃ©bec, Qc, Canada).</p><p>CLP257 incubation: CLP257 was dissolved in 200 Âµl DMSO as 100 mM stock solution and diluted using aCSF to 100 ÂµM. For slice recording, hippocampal slices (350 Î¼m thick) of <italic>App<sup>-/-</sup></italic> mice were cut using a vibratome (LeicaVT1000S) as described above for whole-cell recording in acute hippocampal slices. Slices were incubated for 2 hr in aCSF containing 100 Î¼M CLP257 or DMSO and babbled with 95% O<sub>2</sub> and 5% CO<sub>2</sub>. For surface and total KCC2 protein levels evaluation, HEK293 cells, which was transfected with KCC2 were incubated for 2 hr in 100 Î¼M CLP257 or DMSO.</p><p>CLP290 intraperitoneal injection: CLP290 was dissolved in HPCD and intraperitoneally administered once daily at a dose of 100 mg/kg for one week. HPCD injection group was used as vehicle control.</p></sec><sec id="s4-12"><title>Statistical analysis</title><p>Unless otherwise stated, data are displayed as meanÂ±SEM. Studentâs <italic>t</italic>-test was used for statistical analysis in two-group comparison. For comparison among multiple groups, one-way ANOVA or two-way ANOVA with post hoc tests were used. Statistical significance was set at p&lt;0.05.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors thank Dr. Yasunori Hayashi for suggestions on the manuscript; Zhijie Zhang for technical support. This work was supported by grants from the National Natural Science Foundation of China (31171018, 31171355), the Science and Technology Division of Guangdong (2013KJCX0054, 201607010320), and the Natural Science Foundation of Guangdong Province (2014A030313418, 2014 A030313440).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>MC, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con2"><p>JW, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con3"><p>JJ, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con4"><p>XZ, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con5"><p>NJJ, Acquisition of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con6"><p>KW, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con7"><p>XR, Worked on HEK293 cell culture and transfection</p></fn><fn fn-type="con" id="con8"><p>YL, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con9"><p>QH, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con10"><p>JZ, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con11"><p>HL, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con12"><p>NL, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con13"><p>YW, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con14"><p>HZ, Analysis and interpretation of data, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con15"><p>CL, Analysis and interpretation of data, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con16"><p>LY, Conception and design, Drafting or revising the article</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was conducted along the guidelines described in &quot;The Guide for the Care and Use of Laboratory Animals&quot; (Eighth Edition). All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#0312-11) of the South China Normal University. Every effort was made to minimize suffering.</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Ari</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Excitatory actions of gaba during development: the nature of the nurture</article-title><source>Nature Reviews Neuroscience</source><volume>3</volume><fpage>728</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1038/nrn920</pub-id><pub-id pub-id-type="pmid">12209121</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Ari</surname><given-names>Y</given-names></name><name><surname>Khalilov</surname><given-names>I</given-names></name><name><surname>Kahle</surname><given-names>KT</given-names></name><name><surname>Cherubini</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The GABA excitatory/inhibitory shift in brain maturation and neurological disorders</article-title><source>The Neuroscientist</source><volume>18</volume><fpage>467</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1177/1073858412438697</pub-id><pub-id pub-id-type="pmid">22547529</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname><given-names>R</given-names></name><name><surname>Broutman</surname><given-names>G</given-names></name><name><surname>Foy</surname><given-names>MR</given-names></name><name><surname>Thompson</surname><given-names>RF</given-names></name><name><surname>Baudry</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus</article-title><source>PNAS</source><volume>97</volume><fpage>3602</fpage><lpage>3607</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.7.3602</pub-id><pub-id pub-id-type="pmid">10725383</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaesse</surname><given-names>P</given-names></name><name><surname>Airaksinen</surname><given-names>MS</given-names></name><name><surname>Rivera</surname><given-names>C</given-names></name><name><surname>Kaila</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cation-chloride cotransporters and neuronal function</article-title><source>Neuron</source><volume>61</volume><fpage>820</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2009.03.003</pub-id><pub-id pub-id-type="pmid">19323993</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulenguez</surname><given-names>P</given-names></name><name><surname>Liabeuf</surname><given-names>S</given-names></name><name><surname>Bos</surname><given-names>R</given-names></name><name><surname>Bras</surname><given-names>H</given-names></name><name><surname>Jean-Xavier</surname><given-names>C</given-names></name><name><surname>Brocard</surname><given-names>C</given-names></name><name><surname>Stil</surname><given-names>A</given-names></name><name><surname>Darbon</surname><given-names>P</given-names></name><name><surname>Cattaert</surname><given-names>D</given-names></name><name><surname>Delpire</surname><given-names>E</given-names></name><name><surname>Marsala</surname><given-names>M</given-names></name><name><surname>Vinay</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Down-regulation of the potassium-chloride cotransporter KCC2 contributes to spasticity after spinal cord injury</article-title><source>Nature Medicine</source><volume>16</volume><fpage>302</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1038/nm.2107</pub-id><pub-id pub-id-type="pmid">20190766</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braat</surname><given-names>S</given-names></name><name><surname>Kooy</surname><given-names>RF</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>The GABAA receptor as a therapeutic target for neurodevelopmental disorders</article-title><source>Neuron</source><volume>86</volume><fpage>1119</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2015.03.042</pub-id><pub-id pub-id-type="pmid">26050032</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braat</surname><given-names>S</given-names></name><name><surname>Kooy</surname><given-names>RF</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>The GABAA receptor as a therapeutic target for neurodevelopmental disorders</article-title><source>Neuron</source><volume>86</volume><fpage>1119</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2015.03.042</pub-id><pub-id pub-id-type="pmid">26050032</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caraiscos</surname><given-names>VB</given-names></name><name><surname>Elliott</surname><given-names>EM</given-names></name><name><surname>You-Ten</surname><given-names>KE</given-names></name><name><surname>Cheng</surname><given-names>VY</given-names></name><name><surname>Belelli</surname><given-names>D</given-names></name><name><surname>Newell</surname><given-names>JG</given-names></name><name><surname>Jackson</surname><given-names>MF</given-names></name><name><surname>Lambert</surname><given-names>JJ</given-names></name><name><surname>Rosahl</surname><given-names>TW</given-names></name><name><surname>Wafford</surname><given-names>KA</given-names></name><name><surname>MacDonald</surname><given-names>JF</given-names></name><name><surname>Orser</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by alpha5 subunit-containing gamma-aminobutyric acid type A receptors</article-title><source>PNAS</source><volume>101</volume><fpage>3662</fpage><lpage>3667</lpage><pub-id pub-id-type="doi">10.1073/pnas.0307231101</pub-id><pub-id pub-id-type="pmid">14993607</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavas</surname><given-names>J</given-names></name><name><surname>Marty</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Coexistence of excitatory and inhibitory GABA synapses in the cerebellar interneuron network</article-title><source>Journal of Neuroscience</source><volume>23</volume><fpage>2019</fpage><lpage>2031</lpage><pub-id pub-id-type="pmid">12657660</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chudotvorova</surname><given-names>I</given-names></name><name><surname>Ivanov</surname><given-names>A</given-names></name><name><surname>Rama</surname><given-names>S</given-names></name><name><surname>HÃ¼bner</surname><given-names>CA</given-names></name><name><surname>Pellegrino</surname><given-names>C</given-names></name><name><surname>Ben-Ari</surname><given-names>Y</given-names></name><name><surname>Medina</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Early expression of KCC2 in rat hippocampal cultures augments expression of functional GABA synapses</article-title><source>The Journal of Physiology</source><volume>566</volume><fpage>671</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2005.089821</pub-id><pub-id pub-id-type="pmid">15961425</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coull</surname><given-names>JA</given-names></name><name><surname>Boudreau</surname><given-names>D</given-names></name><name><surname>Bachand</surname><given-names>K</given-names></name><name><surname>Prescott</surname><given-names>SA</given-names></name><name><surname>Nault</surname><given-names>F</given-names></name><name><surname>SÃ­k</surname><given-names>A</given-names></name><name><surname>De Koninck</surname><given-names>P</given-names></name><name><surname>De Koninck</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain</article-title><source>Nature</source><volume>424</volume><fpage>938</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1038/nature01868</pub-id><pub-id pub-id-type="pmid">12931188</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curia</surname><given-names>G</given-names></name><name><surname>Papouin</surname><given-names>T</given-names></name><name><surname>SÃ©guÃ©la</surname><given-names>P</given-names></name><name><surname>Avoli</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome</article-title><source>Cerebral Cortex</source><volume>19</volume><fpage>1515</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhn159</pub-id><pub-id pub-id-type="pmid">18787232</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Strooper</surname><given-names>B</given-names></name><name><surname>Annaert</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Proteolytic processing and cell biological functions of the amyloid precursor protein</article-title><source>Journal of Cell Science</source><volume>113</volume><fpage>1857</fpage><lpage>1870</lpage><pub-id pub-id-type="pmid">10806097</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferando</surname><given-names>I</given-names></name><name><surname>Faas</surname><given-names>GC</given-names></name><name><surname>Mody</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Diminished KCC2 confounds synapse specificity of LTP during senescence</article-title><source>Nature Neuroscience</source><volume>19</volume><fpage>1197</fpage><lpage>1200</lpage><pub-id pub-id-type="doi">10.1038/nn.4357</pub-id><pub-id pub-id-type="pmid">27500406</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiszman</surname><given-names>ML</given-names></name><name><surname>Barberis</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Fu</surname><given-names>Z</given-names></name><name><surname>ErdÃ©lyi</surname><given-names>F</given-names></name><name><surname>SzabÃ³</surname><given-names>G</given-names></name><name><surname>Vicini</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>NMDA receptors increase the size of GABAergic terminals and enhance GABA release</article-title><source>Journal of Neuroscience</source><volume>25</volume><fpage>2024</fpage><lpage>2031</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4980-04.2005</pub-id><pub-id pub-id-type="pmid">15728842</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagnon</surname><given-names>M</given-names></name><name><surname>Bergeron</surname><given-names>MJ</given-names></name><name><surname>Lavertu</surname><given-names>G</given-names></name><name><surname>Castonguay</surname><given-names>A</given-names></name><name><surname>Tripathy</surname><given-names>S</given-names></name><name><surname>Bonin</surname><given-names>RP</given-names></name><name><surname>Perez-Sanchez</surname><given-names>J</given-names></name><name><surname>Boudreau</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Dumas</surname><given-names>L</given-names></name><name><surname>Valade</surname><given-names>I</given-names></name><name><surname>Bachand</surname><given-names>K</given-names></name><name><surname>Jacob-Wagner</surname><given-names>M</given-names></name><name><surname>Tardif</surname><given-names>C</given-names></name><name><surname>Kianicka</surname><given-names>I</given-names></name><name><surname>Isenring</surname><given-names>P</given-names></name><name><surname>Attardo</surname><given-names>G</given-names></name><name><surname>Coull</surname><given-names>JA</given-names></name><name><surname>De Koninck</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Chloride extrusion enhancers as novel therapeutics for neurological diseases</article-title><source>Nature Medicine</source><volume>19</volume><fpage>1524</fpage><lpage>1528</lpage><pub-id pub-id-type="doi">10.1038/nm.3356</pub-id><pub-id pub-id-type="pmid">24097188</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gauvain</surname><given-names>G</given-names></name><name><surname>Chamma</surname><given-names>I</given-names></name><name><surname>Chevy</surname><given-names>Q</given-names></name><name><surname>Cabezas</surname><given-names>C</given-names></name><name><surname>Irinopoulou</surname><given-names>T</given-names></name><name><surname>Bodrug</surname><given-names>N</given-names></name><name><surname>Carnaud</surname><given-names>M</given-names></name><name><surname>LÃ©vi</surname><given-names>S</given-names></name><name><surname>Poncer</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The neuronal K-Cl cotransporter KCC2 influences postsynaptic AMPA receptor content and lateral diffusion in dendritic spines</article-title><source>PNAS</source><volume>108</volume><fpage>15474</fpage><lpage>15479</lpage><pub-id pub-id-type="doi">10.1073/pnas.1107893108</pub-id><pub-id pub-id-type="pmid">21878564</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goswami</surname><given-names>SP</given-names></name><name><surname>Bucurenciu</surname><given-names>I</given-names></name><name><surname>Jonas</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Miniature IPSCs in hippocampal granule cells are triggered by voltage-gated Ca2+ channels via microdomain coupling</article-title><source>Journal of Neuroscience</source><volume>32</volume><fpage>14294</fpage><lpage>14304</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.6104-11.2012</pub-id><pub-id pub-id-type="pmid">23055500</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>FL</given-names></name><name><surname>Smiley</surname><given-names>J</given-names></name><name><surname>Russell</surname><given-names>WC</given-names></name><name><surname>Nairn</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1977">1977</year><article-title>Characteristics of a human cell line transformed by DNA from human adenovirus type 5</article-title><source>Journal of General Virology</source><volume>36</volume><fpage>59</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-36-1-59</pub-id><pub-id pub-id-type="pmid">886304</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Tai</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>CJ</given-names></name><name><surname>Scheuer</surname><given-names>T</given-names></name><name><surname>Catterall</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Enhancement of inhibitory neurotransmission by GABAA receptors having Î±2,3-subunits ameliorates behavioral deficits in a mouse model of autism</article-title><source>Neuron</source><volume>81</volume><fpage>1282</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.01.016</pub-id><pub-id pub-id-type="pmid">24656250</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics</article-title><source>Science</source><volume>297</volume><fpage>353</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1126/science.1072994</pub-id><pub-id pub-id-type="pmid">12130773</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>H</given-names></name><name><surname>Boehm</surname><given-names>J</given-names></name><name><surname>Sato</surname><given-names>C</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Tomita</surname><given-names>T</given-names></name><name><surname>Sisodia</surname><given-names>S</given-names></name><name><surname>Malinow</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss</article-title><source>Neuron</source><volume>52</volume><fpage>831</fpage><lpage>843</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2006.10.035</pub-id><pub-id pub-id-type="pmid">17145504</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>S</given-names></name><name><surname>Yarishkin</surname><given-names>O</given-names></name><name><surname>Hwang</surname><given-names>YJ</given-names></name><name><surname>Chun</surname><given-names>YE</given-names></name><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Woo</surname><given-names>DH</given-names></name><name><surname>Bae</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Chun</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>DY</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>HY</given-names></name><name><surname>Oh</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Yoon</surname><given-names>BE</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Jeong</surname><given-names>Y</given-names></name><name><surname>Shim</surname><given-names>I</given-names></name><name><surname>Bae</surname><given-names>YC</given-names></name><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Kowall</surname><given-names>NW</given-names></name><name><surname>Ryu</surname><given-names>H</given-names></name><name><surname>Hwang</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease</article-title><source>Nature Medicine</source><volume>20</volume><fpage>886</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1038/nm.3639</pub-id><pub-id pub-id-type="pmid">24973918</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaila</surname><given-names>K</given-names></name><name><surname>Price</surname><given-names>TJ</given-names></name><name><surname>Payne</surname><given-names>JA</given-names></name><name><surname>Puskarjov</surname><given-names>M</given-names></name><name><surname>Voipio</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cation-chloride cotransporters in neuronal development, plasticity and disease</article-title><source>Nature Reviews Neuroscience</source><volume>15</volume><fpage>637</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1038/nrn3819</pub-id><pub-id pub-id-type="pmid">25234263</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamenetz</surname><given-names>F</given-names></name><name><surname>Tomita</surname><given-names>T</given-names></name><name><surname>Hsieh</surname><given-names>H</given-names></name><name><surname>Seabrook</surname><given-names>G</given-names></name><name><surname>Borchelt</surname><given-names>D</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Sisodia</surname><given-names>S</given-names></name><name><surname>Malinow</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>APP processing and synaptic function</article-title><source>Neuron</source><volume>37</volume><fpage>925</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(03)00124-7</pub-id><pub-id pub-id-type="pmid">12670422</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Tang</surname><given-names>YP</given-names></name><name><surname>Sisodia</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Abeta star: a light onto synaptic dysfunction?</article-title><source>Nature Medicine</source><volume>12</volume><fpage>760</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1038/nm0706-760</pub-id><pub-id pub-id-type="pmid">16829934</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klevanski</surname><given-names>M</given-names></name><name><surname>Herrmann</surname><given-names>U</given-names></name><name><surname>Weyer</surname><given-names>SW</given-names></name><name><surname>Fol</surname><given-names>R</given-names></name><name><surname>Cartier</surname><given-names>N</given-names></name><name><surname>Wolfer</surname><given-names>DP</given-names></name><name><surname>Caldwell</surname><given-names>JH</given-names></name><name><surname>Korte</surname><given-names>M</given-names></name><name><surname>MÃ¼ller</surname><given-names>UC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The APP intracellular domain is required for normal synaptic morphology, Synaptic Plasticity, and Hippocampus-Dependent Behavior</article-title><source>Journal of Neuroscience</source><volume>35</volume><fpage>16018</fpage><lpage>16033</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2009-15.2015</pub-id><pub-id pub-id-type="pmid">26658856</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HH</given-names></name><name><surname>Walker</surname><given-names>JA</given-names></name><name><surname>Williams</surname><given-names>JR</given-names></name><name><surname>Goodier</surname><given-names>RJ</given-names></name><name><surname>Payne</surname><given-names>JA</given-names></name><name><surname>Moss</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Direct protein kinase C-dependent phosphorylation regulates the cell surface stability and activity of the potassium chloride cotransporter KCC2</article-title><source>Journal of Biological Chemistry</source><volume>282</volume><fpage>29777</fpage><lpage>29784</lpage><pub-id pub-id-type="doi">10.1074/jbc.M705053200</pub-id><pub-id pub-id-type="pmid">17693402</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HH</given-names></name><name><surname>Jurd</surname><given-names>R</given-names></name><name><surname>Moss</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Tyrosine phosphorylation regulates the membrane trafficking of the potassium chloride co-transporter KCC2</article-title><source>Molecular and Cellular Neuroscience</source><volume>45</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2010.06.008</pub-id><pub-id pub-id-type="pmid">20600929</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HH</given-names></name><name><surname>Deeb</surname><given-names>TZ</given-names></name><name><surname>Walker</surname><given-names>JA</given-names></name><name><surname>Davies</surname><given-names>PA</given-names></name><name><surname>Moss</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>NMDA receptor activity downregulates KCC2 resulting in depolarizing GABAA receptor-mediated currents</article-title><source>Nature Neuroscience</source><volume>14</volume><fpage>736</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1038/nn.2806</pub-id><pub-id pub-id-type="pmid">21532577</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Tabuchi</surname><given-names>K</given-names></name><name><surname>Hammer</surname><given-names>RE</given-names></name><name><surname>SÃ¼dhof</surname><given-names>TC</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP</article-title><source>PNAS</source><volume>107</volume><fpage>17362</fpage><lpage>17367</lpage><pub-id pub-id-type="doi">10.1073/pnas.1012568107</pub-id><pub-id pub-id-type="pmid">20855613</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palop</surname><given-names>JJ</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks</article-title><source>Nature Neuroscience</source><volume>13</volume><fpage>812</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1038/nn.2583</pub-id><pub-id pub-id-type="pmid">20581818</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plotkin</surname><given-names>MD</given-names></name><name><surname>Snyder</surname><given-names>EY</given-names></name><name><surname>Hebert</surname><given-names>SC</given-names></name><name><surname>Delpire</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Expression of the Na-K-2Cl cotransporter is developmentally regulated in postnatal rat brains: a possible mechanism underlying GABA's excitatory role in immature brain</article-title><source>Journal of Neurobiology</source><volume>33</volume><fpage>781</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-4695(19971120)33:6&lt;781::AID-NEU6&gt;3.0.CO;2-5</pub-id><pub-id pub-id-type="pmid">9369151</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priller</surname><given-names>C</given-names></name><name><surname>Bauer</surname><given-names>T</given-names></name><name><surname>Mitteregger</surname><given-names>G</given-names></name><name><surname>Krebs</surname><given-names>B</given-names></name><name><surname>Kretzschmar</surname><given-names>HA</given-names></name><name><surname>Herms</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Synapse formation and function is modulated by the amyloid precursor protein</article-title><source>Journal of Neuroscience</source><volume>26</volume><fpage>7212</fpage><lpage>7221</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1450-06.2006</pub-id><pub-id pub-id-type="pmid">16822978</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>C</given-names></name><name><surname>Voipio</surname><given-names>J</given-names></name><name><surname>Payne</surname><given-names>JA</given-names></name><name><surname>Ruusuvuori</surname><given-names>E</given-names></name><name><surname>Lahtinen</surname><given-names>H</given-names></name><name><surname>Lamsa</surname><given-names>K</given-names></name><name><surname>Pirvola</surname><given-names>U</given-names></name><name><surname>Saarma</surname><given-names>M</given-names></name><name><surname>Kaila</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The K+/Cl- co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation</article-title><source>Nature</source><volume>397</volume><fpage>251</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1038/16697</pub-id><pub-id pub-id-type="pmid">9930699</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saliba</surname><given-names>RS</given-names></name><name><surname>Pangalos</surname><given-names>M</given-names></name><name><surname>Moss</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The ubiquitin-like protein Plic-1 enhances the membrane insertion of GABAA receptors by increasing their stability within the endoplasmic reticulum</article-title><source>Journal of Biological Chemistry</source><volume>283</volume><fpage>18538</fpage><lpage>18544</lpage><pub-id pub-id-type="doi">10.1074/jbc.M802077200</pub-id><pub-id pub-id-type="pmid">18467327</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savas</surname><given-names>JN</given-names></name><name><surname>Ribeiro</surname><given-names>LF</given-names></name><name><surname>Wierda</surname><given-names>KD</given-names></name><name><surname>Wright</surname><given-names>R</given-names></name><name><surname>DeNardo-Wilke</surname><given-names>LA</given-names></name><name><surname>Rice</surname><given-names>HC</given-names></name><name><surname>Chamma</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>YZ</given-names></name><name><surname>Zemla</surname><given-names>R</given-names></name><name><surname>LavallÃ©e-Adam</surname><given-names>M</given-names></name><name><surname>Vennekens</surname><given-names>KM</given-names></name><name><surname>O'Sullivan</surname><given-names>ML</given-names></name><name><surname>Antonios</surname><given-names>JK</given-names></name><name><surname>Hall</surname><given-names>EA</given-names></name><name><surname>Thoumine</surname><given-names>O</given-names></name><name><surname>Attie</surname><given-names>AD</given-names></name><name><surname>Yates</surname><given-names>JR</given-names></name><name><surname>Ghosh</surname><given-names>A</given-names></name><name><surname>de Wit</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The sorting receptor SorCS1 regulates trafficking of neurexin and AMPA receptors</article-title><source>Neuron</source><volume>87</volume><fpage>764</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2015.08.007</pub-id><pub-id pub-id-type="pmid">26291160</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schubert</surname><given-names>W</given-names></name><name><surname>Prior</surname><given-names>R</given-names></name><name><surname>Weidemann</surname><given-names>A</given-names></name><name><surname>Dircksen</surname><given-names>H</given-names></name><name><surname>Multhaup</surname><given-names>G</given-names></name><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Beyreuther</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Localization of alzheimer beta A4 amyloid precursor protein at central and peripheral synaptic sites</article-title><source>Brain Research</source><volume>563</volume><fpage>184</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(91)91532-6</pub-id><pub-id pub-id-type="pmid">1786532</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seabrook</surname><given-names>GR</given-names></name><name><surname>Smith</surname><given-names>DW</given-names></name><name><surname>Bowery</surname><given-names>BJ</given-names></name><name><surname>Easter</surname><given-names>A</given-names></name><name><surname>Reynolds</surname><given-names>T</given-names></name><name><surname>Fitzjohn</surname><given-names>SM</given-names></name><name><surname>Morton</surname><given-names>RA</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Dawson</surname><given-names>GR</given-names></name><name><surname>Sirinathsinghji</surname><given-names>DJ</given-names></name><name><surname>Davies</surname><given-names>CH</given-names></name><name><surname>Collingridge</surname><given-names>GL</given-names></name><name><surname>Hill</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein</article-title><source>Neuropharmacology</source><volume>38</volume><fpage>349</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1016/S0028-3908(98)00204-4</pub-id><pub-id pub-id-type="pmid">10219973</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Alzheimer's disease is a synaptic failure</article-title><source>Science</source><volume>298</volume><fpage>789</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1126/science.1074069</pub-id><pub-id pub-id-type="pmid">12399581</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Succol</surname><given-names>F</given-names></name><name><surname>Fiumelli</surname><given-names>H</given-names></name><name><surname>Benfenati</surname><given-names>F</given-names></name><name><surname>Cancedda</surname><given-names>L</given-names></name><name><surname>Barberis</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Intracellular chloride concentration influences the GABAA receptor subunit composition</article-title><source>Nature Communications</source><volume>3</volume><fpage>738</fpage><pub-id pub-id-type="doi">10.1038/ncomms1744</pub-id><pub-id pub-id-type="pmid">22415829</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>SÃ¶derberg</surname><given-names>O</given-names></name><name><surname>Gullberg</surname><given-names>M</given-names></name><name><surname>Jarvius</surname><given-names>M</given-names></name><name><surname>RidderstrÃ¥le</surname><given-names>K</given-names></name><name><surname>Leuchowius</surname><given-names>KJ</given-names></name><name><surname>Jarvius</surname><given-names>J</given-names></name><name><surname>Wester</surname><given-names>K</given-names></name><name><surname>Hydbring</surname><given-names>P</given-names></name><name><surname>Bahram</surname><given-names>F</given-names></name><name><surname>Larsson</surname><given-names>LG</given-names></name><name><surname>Landegren</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Direct observation of individual endogenous protein complexes in situ by proximity ligation</article-title><source>Nature Methods</source><volume>3</volume><fpage>995</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1038/nmeth947</pub-id><pub-id pub-id-type="pmid">17072308</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamamaki</surname><given-names>N</given-names></name><name><surname>Yanagawa</surname><given-names>Y</given-names></name><name><surname>Tomioka</surname><given-names>R</given-names></name><name><surname>Miyazaki</surname><given-names>J</given-names></name><name><surname>Obata</surname><given-names>K</given-names></name><name><surname>Kaneko</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Green fluorescent protein expression and colocalization with calretinin, parvalbumin, and somatostatin in the GAD67-GFP knock-in mouse</article-title><source>The Journal of Comparative Neurology</source><volume>467</volume><fpage>60</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1002/cne.10905</pub-id><pub-id pub-id-type="pmid">14574680</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Wengert</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Carromeu</surname><given-names>C</given-names></name><name><surname>Muotri</surname><given-names>AR</given-names></name><name><surname>Marchetto</surname><given-names>MC</given-names></name><name><surname>Gage</surname><given-names>FH</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>KCC2 rescues functional deficits in human neurons derived from patients with Rett syndrome</article-title><source>PNAS</source><volume>113</volume><fpage>751</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1073/pnas.1524013113</pub-id><pub-id pub-id-type="pmid">26733678</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Newburn</surname><given-names>EN</given-names></name><name><surname>Ye</surname><given-names>T</given-names></name><name><surname>Lipska</surname><given-names>BK</given-names></name><name><surname>Herman</surname><given-names>MM</given-names></name><name><surname>Weinberger</surname><given-names>DR</given-names></name><name><surname>Kleinman</surname><given-names>JE</given-names></name><name><surname>Hyde</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Transcript-specific associations of SLC12A5 (KCC2) in human prefrontal cortex with development, schizophrenia, and affective disorders</article-title><source>Journal of Neuroscience</source><volume>32</volume><fpage>5216</fpage><lpage>5222</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4626-11.2012</pub-id><pub-id pub-id-type="pmid">22496567</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verret</surname><given-names>L</given-names></name><name><surname>Mann</surname><given-names>EO</given-names></name><name><surname>Hang</surname><given-names>GB</given-names></name><name><surname>Barth</surname><given-names>AM</given-names></name><name><surname>Cobos</surname><given-names>I</given-names></name><name><surname>Ho</surname><given-names>K</given-names></name><name><surname>Devidze</surname><given-names>N</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Kreitzer</surname><given-names>AC</given-names></name><name><surname>Mody</surname><given-names>I</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name><name><surname>Palop</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in alzheimer model</article-title><source>Cell</source><volume>149</volume><fpage>708</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.02.046</pub-id><pub-id pub-id-type="pmid">22541439</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wake</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Moorhouse</surname><given-names>AJ</given-names></name><name><surname>Kanematsu</surname><given-names>T</given-names></name><name><surname>Horibe</surname><given-names>S</given-names></name><name><surname>Matsukawa</surname><given-names>N</given-names></name><name><surname>Asai</surname><given-names>K</given-names></name><name><surname>Ojika</surname><given-names>K</given-names></name><name><surname>Hirata</surname><given-names>M</given-names></name><name><surname>Nabekura</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Early changes in KCC2 phosphorylation in response to neuronal stress result in functional downregulation</article-title><source>Journal of Neuroscience</source><volume>27</volume><fpage>1642</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3104-06.2007</pub-id><pub-id pub-id-type="pmid">17301172</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Amyolid precursor protein mediates presynaptic localization and activity of the high-affinity choline transporter</article-title><source>PNAS</source><volume>104</volume><fpage>14140</fpage><lpage>14145</lpage><pub-id pub-id-type="doi">10.1073/pnas.0704070104</pub-id><pub-id pub-id-type="pmid">17709753</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Aithmitti</surname><given-names>N</given-names></name><name><surname>Songyang</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Presynaptic and postsynaptic interaction of the amyloid precursor protein promotes peripheral and central synaptogenesis</article-title><source>Journal of Neuroscience</source><volume>29</volume><fpage>10788</fpage><lpage>10801</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2132-09.2009</pub-id><pub-id pub-id-type="pmid">19726636</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Cole</surname><given-names>AL</given-names></name><name><surname>Rodriguez-Rivera</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>H-C</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014a</year><article-title>The amyloid precursor protein controls adult hippocampal neurogenesis through GABAergic interneurons</article-title><source>Journal of Neuroscience</source><volume>34</volume><fpage>13314</fpage><lpage>13325</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2848-14.2014</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Cole</surname><given-names>AL</given-names></name><name><surname>Rodriguez-Rivera</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>HC</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014b</year><article-title>The amyloid precursor protein controls adult hippocampal neurogenesis through GABAergic interneurons</article-title><source>Journal of Neuroscience</source><volume>34</volume><fpage>13314</fpage><lpage>13325</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2848-14.2014</pub-id><pub-id pub-id-type="pmid">25274811</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Nguyen</surname><given-names>LN</given-names></name><name><surname>Kessels</surname><given-names>HW</given-names></name><name><surname>Hagiwara</surname><given-names>H</given-names></name><name><surname>Sisodia</surname><given-names>S</given-names></name><name><surname>Malinow</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Amyloid beta from axons and dendrites reduces local spine number and plasticity</article-title><source>Nature Neuroscience</source><volume>13</volume><fpage>190</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1038/nn.2476</pub-id><pub-id pub-id-type="pmid">20037574</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Gearing</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an alzheimer's [corrected] disease model</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>4159</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms5159</pub-id><pub-id pub-id-type="pmid">24923909</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Long</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Increased asynchronous release and aberrant calcium channel activation in amyloid precursor protein deficient neuromuscular synapses</article-title><source>Neuroscience</source><volume>149</volume><fpage>768</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2007.08.025</pub-id><pub-id pub-id-type="pmid">17919826</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Justice</surname><given-names>NJ</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Amyloid precursor protein regulates Cav1.2 L-type calcium channel levels and function to influence GABAergic short-term plasticity</article-title><source>Journal of Neuroscience</source><volume>29</volume><fpage>15660</fpage><lpage>15668</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4104-09.2009</pub-id><pub-id pub-id-type="pmid">20016080</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yarishkin</surname><given-names>O</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Jo</surname><given-names>S</given-names></name><name><surname>Hwang</surname><given-names>EM</given-names></name><name><surname>Lee</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Disinhibitory action of astrocytic GABA at the perforant path to dentate gyrus granule neuron synapse reverses to inhibitory in Alzheimer's Disease Model</article-title><source>Experimental Neurobiology</source><volume>24</volume><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.5607/en.2015.24.3.211</pub-id><pub-id pub-id-type="pmid">26412970</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Trumbauer</surname><given-names>ME</given-names></name><name><surname>Sirinathsinghji</surname><given-names>DJ</given-names></name><name><surname>Hopkins</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>DW</given-names></name><name><surname>Heavens</surname><given-names>RP</given-names></name><name><surname>Dawson</surname><given-names>GR</given-names></name><name><surname>Boyce</surname><given-names>S</given-names></name><name><surname>Conner</surname><given-names>MW</given-names></name><name><surname>Stevens</surname><given-names>KA</given-names></name><name><surname>Slunt</surname><given-names>HH</given-names></name><name><surname>Sisoda</surname><given-names>SS</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Van der Ploeg</surname><given-names>LH</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity</article-title><source>Cell</source><volume>81</volume><fpage>525</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90073-X</pub-id><pub-id pub-id-type="pmid">7758106</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zucker</surname><given-names>RS</given-names></name><name><surname>Regehr</surname><given-names>WG</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Short-term synaptic plasticity</article-title><source>Annual Review of Physiology</source><volume>64</volume><fpage>355</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1146/annurev.physiol.64.092501.114547</pub-id><pub-id pub-id-type="pmid">11826273</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.20142.026</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kim</surname><given-names>Eunjoon</given-names></name><role>Reviewing editor</role><aff id="aff8"><institution>Institute for Basic Science, Korea Advanced Institute of Science and Technology</institution>, <country>Republic of Korea</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;APP is a novel protein-binding partner for KCC2: An insight on the role of APP in hippocampal GABAAR mediated inhibition&quot; for consideration by <italic>eLife</italic>. Your article has been favorably evaluated by a Senior Editor and three reviewers, one of whom is a member of our Board of Reviewing Editors. The following individual involved in review of your submission has agreed to reveal his identity: C Justin Lee (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>This study provides some evidence that APP stabilizes KCC2, a K<sup>+</sup>-Cl<sup>-</sup> cotransporter, on the cell surface and that APP regulates GABAA receptor-mediated synaptic transmission. The authors first showed the GABA reversal potential shifts toward depolarization, the decreased unitary IPSC amplitude, and the reduced GABAA receptor protein level in the hippocampus of APP-/- mice. Then, the authors found that APP directly binds to KCC2 and prevents KCC2 from its degradation. Furthermore, the authors showed that restoration of KCC2 function in APP-/- mice by CLP290 rescues GABAA receptor levels and function. Because patho-physiological functions of APP have attracted considerable attention, this work addresses a generally important topic. Addressing the following points would strengthen this paper.</p><p>Essential revisions:</p><p>1) The authors provide data suggesting that KCC2 in the absence of APP is degraded through ubiquitin-dependent mechanisms and enhanced endocytosis. However, the data supporting this conclusion mainly presented in <xref ref-type="fig" rid="fig6">Figure 6</xref> are very weak. Specifically, there is no evidence supporting that APP2 deficiency causes KCC2 ubiquitination or KCC2 endocytosis. In addition, it is unclear whether endocytosis of KCC2 is functionally coupled to ubiquitination.</p><p>2) Although the link between APP and KCC2 is abundantly clear, the link between KCC2 and GABAA is not so clear. For example, in <xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref> there appears to be a significant difference in Egaba between WT and APP-/-. However, there appears to be a difference in the conductance (slope of the IV) between whole cell (<xref ref-type="fig" rid="fig1">Figure 1</xref>) in slice and perforated patch (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>) in culture. This type of discrepancy is also shown in <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>, in which the amplitude of mIPSC for WT and APP-/- did not show the expected difference. These discrepancies might be due to the fact that authors apparently do not fully address the field of GABA inhibition. GABA has not only phasic mode but also tonic mode of action. In recent studies, tonic GABA release from reactive astrocytes and its inhibitory action has been implicated in Alzheimer's disease (Jo, et al., 2012; Wang, et al., 2012; also, see Yarishkin et al., 2015). KCC2 could not only affect synaptic GABAA receptors but also extrasynaptic GABAA receptors. In addition, isoguvacine which is used for monitoring functional surface GABAA activates not only synaptic GABAA but also extrasynaptic GABAA, complicating authors' interpretations. Therefore, authors need to introduce the current state of phasic and tonic GABA appropriately and discuss their results accordingly.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.20142.027</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>Essential revisions:</italic> </p><p><italic>1) The authors provide data suggesting that KCC2 in the absence of APP is degraded through ubiquitin-dependent mechanisms and enhanced endocytosis. However, the data supporting this conclusion mainly presented in <xref ref-type="fig" rid="fig6">Figure 6</xref> are very weak. Specifically, there is no evidence supporting that APP2 deficiency causes KCC2 ubiquitination or KCC2 endocytosis. In addition, it is unclear whether endocytosis of KCC2 is functionally coupled to ubiquitination.</italic> </p><p>We would like to thank the reviewers for these questions about the KCC2 ubiquitination phenotype in APP<sup>-/-</sup> mice. In our original submission, we showed that, in HEK293 cells, mKCC2 (a mutant form of KCC2 in which tyrosine phosphorylation is inhibited) underwent ubiquitination and sequential degradation in the absence of APP co-transfection based on experiment showing that mKCC2 levels could be rescued by co-transfection with CYLD (a deubiquitinating enzyme) construct (previously <xref ref-type="fig" rid="fig6">Figure 6</xref>, now <xref ref-type="fig" rid="fig7">Figure 7</xref>), implicating ubiquitination as a mechanism potentially leading to KCC2 degradation. In our new experiments, we have confirmed, by treating transfected HEK293 cells (mKCC2 alone, mKCC2+APP; KCC2 alone, KCC2+APP) with the ubiquitination inhibitor MG132 (or vehicle), that blockade of ubiquitination by MG132 significantly increased both KCC2 and mKCC2 levels in the absence of APP (<xref ref-type="fig" rid="fig8">Figure 8A-D</xref> in the revised manuscript).</p><p>These data in HEK293 cells implicate that APP deficiency might result in enhanced KCC2 ubiquitination, which contributes, at least in part, to reduced KCC2 levels in APP<sup>-/-</sup> hippocampus. To determine whether KCC2 ubiquitination occurs in brain lysates as well, we immunoprecipitated KCC2 from APP<sup>-/-</sup> and WT mouse hippocampal lysates and immunoblotted for ubiquitin/ubiquitinated protein to evaluate differences in KCC2 ubiquitination in APP<sup>-/-</sup> and WT. In APP<sup>-/-</sup> extracts, we observed significantly increased levels of ubiquitinated KCC2, indicating increased KCC2 ubiquitination in APP<sup>-/-</sup> hippocampus (<xref ref-type="fig" rid="fig8">Figure 8E-F</xref>). Furthermore, KCC2 levels were significantly increased in MG132-treated APP<sup>-/-</sup> hippocampus compared to DMSO controls (<xref ref-type="fig" rid="fig8">Figure 8G-H</xref>). Moreover, MG132 treatment increased KCC2 surface levels in both HEK293 cells and APP<sup>-/-</sup> hippocampus (<xref ref-type="fig" rid="fig8">Figure 8I-J</xref>), implicating that KCC2 endocytosis might be functionally coupled to ubiquitination. Together, these results support the hypothesis that APP deficiency does indeed cause KCC2 ubiquitination. Please see subsection âAPP also functions to suppress ubiquitination and thus degradation of KCC2â and the Discussion, second paragraph.</p><p><italic>2) Although the link between APP and KCC2 is abundantly clear, the link between KCC2 and GABAA is not so clear. For example, in <xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref> there appears to be a significant difference in Egaba between WT and APP-/-. However, there appears to be a difference in the conductance (slope of the IV) between whole cell (<xref ref-type="fig" rid="fig1">Figure 1</xref>) in slice and perforated patch (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>) in culture. This type of discrepancy is also shown in <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>, in which the amplitude of mIPSC for WT and APP-/- did not show the expected difference. These discrepancies might be due to the fact that authors apparently do not fully address the field of GABA inhibition. GABA has not only phasic mode but also tonic mode of action. In recent studies, tonic GABA release from reactive astrocytes and its inhibitory action has been implicated in Alzheimer's disease (Jo, et al., 2012; Wang, et al., 2012; also, see Yarishkin et al., 2015). KCC2 could not only affect synaptic GABAA receptors but also extrasynaptic GABAA receptors. In addition, isoguvacine which is used for monitoring functional surface GABAA activates not only synaptic GABAA but also extrasynaptic GABAA, complicating authors' interpretations. Therefore, authors need to introduce the current state of phasic and tonic GABA appropriately and discuss their results accordingly.</italic> </p><p>We greatly appreciate the advice that we do a more extensive phenotypic analysis to introduce the current state of phasic and tonic GABA appropriately and we feel that this has greatly improved the manuscript. We have previously shown that APP deficiency results in an impairment in tonic GABA current in dentate gyrus (Wang et al., 2014), and we have now added a figure showing significantly reduced tonic GABA current, which was evaluated by application of the GABA<sub>A</sub>R antagonist bicuculline, in CA1 of APP<sup>-/-</sup> mice. Interestingly, restoring KCC2 activity with CLP257 did not rescue the impaired tonic GABA current in APP<sup>-/-</sup> hippocampus (<xref ref-type="fig" rid="fig9">Figure 9A-B</xref>). In addition, using western blotting, we have now shown that there are no significant differences between WT and APP<sup>-/-</sup> mice in levels of GABA<sub>A</sub>R Î±5 and Î´ subunits, which mediate tonic GABA current (Brickley &amp; Mody 2012; Caraiscos et al., 2004; Curia et al., 2009) (data added to <xref ref-type="fig" rid="fig2">Figure 2H-I</xref> in the revised manuscript). These results suggest that altered tonic GABA current in APP-deficient CA1 may involve presynaptic mechanisms, e.g., abnormal astrocytic GABA activities, that require further investigation in the future. The tonic GABA data have been added to the Results and Discussion, respectively.</p><p>We apologize for our lack of clarity. Actually, both <xref ref-type="fig" rid="fig1">Figure 1</xref> (in slice) and <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref> (in culture) are perforated patch experiments. In addition, the differences in conductance between brain slice and culture seen in our present study might also be explained, in part, by E<sub>GABA</sub> differences between brain and culture (Khirug et al., 2005), different internal/external solutions and different perfusion speeds used for recording E<sub>GABA</sub> in slice and culture.</p><p>Please see the subsection âuIPSC amplitude and GABAAR Î±1 subunit levels are reduced in App-/- hippocampusâ of the manuscript for an explanation of the identical amplitude of mIPSC in WT and APP<sup>-/-</sup>.</p></body></sub-article></article>